{"content":"<li class=\"n-box-item date-title\" data-end=\"1493092799\" data-start=\"1493006400\" data-txt=\"Monday, December 23, 2019\">Monday, April 24, 2017</li><li class=\"n-box-item sa-box-item\" data-id=\"3259148\" data-ts=\"1493072651\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/UIS\" target=\"_blank\">UIS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3259148-unisysplus-12_1-narrower-loss-in-q1-beat\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Unisys +12.1% with narrower loss in Q1 beat</a></h4><ul>   <li>Unisys (<a href=\"http://seekingalpha.com/symbol/UIS\" target=\"_blank\">UIS</a> <font color='green'>+1.8%</font>) is <font color='green'>up 12.1%</font> in late trading after <a href=\"https://seekingalpha.com/news/3259093-unisys-beats-0_08-beats-revenue\" target=\"_blank\">Q1 earnings</a> beat on top and bottom lines as margins increased even as revenues declined just short of flat.</li>    <li>On a GAAP basis, the company narrowed its loss per share to $0.65; non-GAAP EPS nearly tripled, to $0.30 from a previous $0.11.</li>    <li>Operating profit rose 370 basis points on a GAAP basis to -0.4%; on a non-GAAP basis, it was 6% (up 340 bps Y/Y).</li>    <li>Revenue breakout: Services, $585.3M (down 1.65%); Technology, $79.2M (up 10.5%).</li>    <li>It's reaffirmed full-year guidance for revenues of $2.65B-$2.75B (vs. consensus for $2.71B), operating profit margin (non-GAAP) of 7.25%-8.25%, and adjusted free cash flow of $130M-$170M</li>    <li><a href=\"https://seekingalpha.com/pr/16808195-unisys-announces-first-quarter-2017-financial-results-re-affirms-full-year-financial-guidance\" target=\"_blank\">Press Release</a></li> </ul><div class=\"tiny-share-widget\" data-id=\"3259148\" data-linked=\"Unisys +12.1% with narrower loss in Q1 beat\" data-tweet=\"$UIS - Unisys +12.1% with narrower loss in Q1 beat https://seekingalpha.com/news/3259148-unisysplus-12_1-narrower-loss-in-q1-beat?source=tweet\" data-url=\"https://seekingalpha.com/news/3259148-unisysplus-12_1-narrower-loss-in-q1-beat\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  6:24 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3259144\" data-ts=\"1493071105\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CDNS\" target=\"_blank\">CDNS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3259144-cadence-design-systemsminus-4_7-on-light-q2-guidance\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Cadence Design Systems -4.7% on light Q2 guidance</a></h4><ul>   <li>Cadence Design Systems (<a href=\"http://seekingalpha.com/symbol/CDNS\" target=\"_blank\">CDNS</a> <font color='green'>+1.8%</font>) has <font color='red'>slipped 4.7%</font> after hours following <a href=\"https://seekingalpha.com/news/3259061-cadence-design-systems-eps-line-beats-revenue\" target=\"_blank\">Q1 earnings</a> that met expectations but featured some downside guidance for Q2.</li>    <li>Revenues grew 6.5% and EPS increased nearly 50% on a GAAP basis, to $0.25. Non-GAAP EPS increased to $0.32 from $0.28.</li>    <li>Cash and equivalents came to $544.1M as of April 1, up from $465.2M at year-end 2016.</li>    <li>Revenue breakout: Product and maintenance, $451.4M (up 9.6%); Services, $25.5M (down 29.4%).</li>    <li>For Q2, it's guiding to revenues of $470M-$480M (below consensus for $480.6M), with non-GAAP EPS forecast at $0.31-$0.33 (below expectations for $0.34). It's reiterating guidance for the full fiscal year, for revenue of $1.9B-$1.95B (vs. consensus for $1.93B) and non-GAAP EPS of $1.34-$1.42 (vs. $1.38 expected).</li>    <li><a href=\"https://seekingalpha.com/pr/16808099-cadence-reports-first-quarter-2017-financial-results\" target=\"_blank\">Press Release</a></li> </ul><div class=\"tiny-share-widget\" data-id=\"3259144\" data-linked=\"Cadence Design Systems -4.7% on light Q2 guidance\" data-tweet=\"$CDNS - Cadence Design Systems -4.7% on light Q2 guidance https://seekingalpha.com/news/3259144-cadence-design-systemsminus-4_7-on-light-q2-guidance?source=tweet\" data-url=\"https://seekingalpha.com/news/3259144-cadence-design-systemsminus-4_7-on-light-q2-guidance\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:58 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3259138\" data-ts=\"1493069899\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3259138-after-hours-gainers-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">After Hours Gainers / Losers</a></h4><ul>     <li><b>Top gainers, as of 5.25 p.m.:</b> <a href='https://seekingalpha.com/symbol/UIS' title='Unisys Corporation'>UIS</a> <font color='green'>+12.6%</font>. <a href='https://seekingalpha.com/symbol/LLNW' title='Limelight Networks, Inc.'>LLNW</a> <font color='green'>+10.6%</font>. <a href='https://seekingalpha.com/symbol/LXU' title='LSB Industries, Inc.'>LXU</a> <font color='green'>+5.4%</font>. <a href='https://seekingalpha.com/symbol/IMGN' title='ImmunoGen, Inc.'>IMGN</a> <font color='green'>+4.9%</font>. <a href='https://seekingalpha.com/symbol/SLCA' title='U.S. Silica'>SLCA</a> <font color='green'>+4.6%</font>.</li><li><b>Top losers, as of 5.25p.m.:</b> <a href='https://seekingalpha.com/symbol/ESRX' title='Express Scripts, Inc.'>ESRX</a> <font color='red'>-14.1%</font>. SWFT <font color='red'>-10.2%</font>. <a href='https://seekingalpha.com/symbol/CDNS' title='Cadence Design Systems, Inc.'>CDNS</a> <font color='red'>-4.7%</font>. <a href='https://seekingalpha.com/symbol/MFG' title='Mizuho Financial Group, Inc.'>MFG</a> <font color='red'>-3.6%</font>. ABX <font color='red'>-3.5%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3259138\" data-linked=\"After Hours Gainers / Losers\" data-tweet=\"$UIS $LLNW $LXU - After Hours Gainers / Losers https://seekingalpha.com/news/3259138-after-hours-gainers-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3259138-after-hours-gainers-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:38 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3259117\" data-ts=\"1493067724\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/HUM\" target=\"_blank\">HUM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3259117-humana-sees-q1-eps-above-consensus-raises-guidance-shares-ahead-2-after-hours\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Humana sees Q1 EPS above consensus, raises guidance; shares ahead 2% after hours</a></h4><ul><li>Humana (NYSE:<a href='https://seekingalpha.com/symbol/HUM' title='Humana Inc.'>HUM</a>)<a href=\"https://seekingalpha.com/pr/16808152-humana-host-biennial-investor-meeting-pre-announces-first-quarter-2017-eps-revenues-increases\" target=\"_blank\"> expects Q1 EPS</a> of $2.75, above the consensus of $2.44, driven by strong performance in the retail segment, specifically Medicare Advantage. The company expects the Medicare rate increase for 2018 to be 0.45%.</li><li><strong>2017 Guidance</strong>: Non-GAAP EPS: at least $11.10, up from $10.80 - 11.00.</li><li>The company will release Q1 results on May 3 before the open.</li><li>Shares are up&nbsp;<font color='green'>2%</font>&nbsp;after hours on light volume.</li></ul><div class=\"tiny-share-widget\" data-id=\"3259117\" data-linked=\"Humana sees Q1 EPS above consensus, raises guidance; shares ahead 2% after hours\" data-tweet=\"$HUM - Humana sees Q1 EPS above consensus, raises guidance; shares ahead 2% after hours https://seekingalpha.com/news/3259117-humana-sees-q1-eps-above-consensus-raises-guidance-shares-ahead-2-after-hours?source=tweet\" data-url=\"https://seekingalpha.com/news/3259117-humana-sees-q1-eps-above-consensus-raises-guidance-shares-ahead-2-after-hours\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:02 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3259106\" data-ts=\"1493066623\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CTRV\" target=\"_blank\">CTRV</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3259106-contravir-readies-equity-offering-shares-slump-28-after-hours\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">ContraVir readies equity offering; shares slump 28% after hours</a></h4><ul><li>Nano cap ContraVir Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/CTRV' title='ContraVir Pharmaceuticals, Inc.'>CTRV</a>) is down<font color='red'> 28%</font>&nbsp;after hours on robust volume in response to its <a href=\"https://seekingalpha.com/pr/16808089-contravir-pharmaceuticals-announces-proposed-public-offering-common-stock-warrants\" target=\"_blank\">announcement </a>of an upcoming equity offering. Price, volume and terms have yet to be announced.</li><li>Today's close was $1.18.</li></ul><div class=\"tiny-share-widget\" data-id=\"3259106\" data-linked=\"ContraVir readies equity offering; shares slump 28% after hours\" data-tweet=\"$CTRV $HEPA - ContraVir readies equity offering; shares slump 28% after hours https://seekingalpha.com/news/3259106-contravir-readies-equity-offering-shares-slump-28-after-hours?source=tweet\" data-url=\"https://seekingalpha.com/news/3259106-contravir-readies-equity-offering-shares-slump-28-after-hours\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:43 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>15&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3259098\" data-ts=\"1493066105\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ESRX\" target=\"_blank\">ESRX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3259098-express-scripts-q1-top-line-flat-earnings-up-4-non-gaap-eps-guidance-raised\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Express Scripts Q1 top line flat; earnings up 4%; non-GAAP EPS guidance raised</a></h4><ul><li>Express Scripts (NASDAQ:<a href='https://seekingalpha.com/symbol/ESRX' title='Express Scripts, Inc.'>ESRX</a>) <a href=\"https://seekingalpha.com/pr/16808071-express-scripts-announces-2017-first-quarter-results-provides-update-anthem-relationship\" target=\"_blank\">Q1 results</a> ($M): Revenues: 24,654.9 (-0.6%).</li><li>Net Income: 546.3 (+3.8%); Non-GAAP Net Income: 805.4 (1.8%); EPS: 0.90 (+11.1%); Non-GAAP EPS: 1.33 (9.0%); CF Ops: 1,000.4 (+33.2%).</li><li>Total claims: 252.1 (-1.7%).</li><li><strong>2017 Guidance</strong>: Non-GAAP EPS: $6.90 - 7.04 from $6.82 - 7.02.</li><li><strong>Q2 Guidance</strong>: Non-GAAP EPS: $1.70 - 1.74; Total Adjusted Claims: 343M - 353M.</li><li>The company's relationship with Anthem (NYSE:<a href='https://seekingalpha.com/symbol/ANTM' title='Anthem, Inc.'>ANTM</a>) has apparently dead-ended. Anthem management has informed ESRX that it has no interest in discussing a continuation of their contract, set to expire on December 31, 2019, despite ESRX offering annual price concessions as high a $1B.</li><li>Shares are unchanged after hours on robust volume.</li><li>PBS competitor CVS Health (NYSE:<a href='https://seekingalpha.com/symbol/CVS' title='CVS Health Corporation'>CVS</a>) is up&nbsp;<font color='green'>2%</font>&nbsp;after hours on robust volume.</li><li><strong>Update</strong>: ESRX is down&nbsp;<font color='red'>11%</font>&nbsp;after hours on robust volume.</li></ul><div class=\"tiny-share-widget\" data-id=\"3259098\" data-linked=\"Express Scripts Q1 top line flat; earnings up 4%; non-GAAP EPS guidance raised\" data-tweet=\"$ESRX $ESRX $ANTM - Express Scripts Q1 top line flat; earnings up 4%; non-GAAP EPS guidance raised https://seekingalpha.com/news/3259098-express-scripts-q1-top-line-flat-earnings-up-4-non-gaap-eps-guidance-raised?source=tweet\" data-url=\"https://seekingalpha.com/news/3259098-express-scripts-q1-top-line-flat-earnings-up-4-non-gaap-eps-guidance-raised\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:35 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>41&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3259093\" data-ts=\"1493065886\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/UIS\" target=\"_blank\">UIS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3259093-unisys-beats-0_08-beats-on-revenue\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Unisys beats by $0.08, beats on revenue</a></h4><ul><li>Unisys (NYSE:<a href='https://seekingalpha.com/symbol/UIS' title='Unisys Corporation'>UIS</a>): Q1 EPS of $0.30 <font color='green'>beats by $0.08</font>.</li><li>Revenue of $665M (-0.3% Y/Y) <font color='green'>beats by $35.62M</font>.</li><li>Shares <font color='green'>+14%</font>.</li><li><a href='https://seekingalpha.com/pr/16808195-unisys-announces-first-quarter-2017-financial-results-re-affirms-full-year-financial-guidance'>Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3259093\" data-linked=\"Unisys beats by $0.08, beats on revenue\" data-tweet=\"$UIS - Unisys beats by $0.08, beats on revenue https://seekingalpha.com/news/3259093-unisys-beats-0_08-beats-on-revenue?source=tweet\" data-url=\"https://seekingalpha.com/news/3259093-unisys-beats-0_08-beats-on-revenue\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:31 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3259046\" data-ts=\"1493063299\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ACHN\" target=\"_blank\">ACHN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3259046-disappointing-mid-stage-data-for-triple-combo-for-hcvminus-3-sinks-achillion-shares-down-12\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Disappointing mid-stage data for triple combo for HCV-3 sinks Achillion; shares down 12%</a></h4><ul><li>Achillion Pharmaceuticals (<a href='https://seekingalpha.com/symbol/ACHN' title='Achillion Pharmaceuticals, Inc.'>ACHN</a> <font color='red'>-12.4%</font>) is on the outside looking in at the market's and biotech's big up move today. Data presented at The International Liver Congress showed a 100% cure rate at weeks 6 and 8 for HCV genotype 1 for the triple combo of simeprevir, odalasvir and AL-335. For HCV genotype 3, though, there was not enough of an efficacy signal to warrant continued development.</li><li>The negative result in the most treatment-resistant HCV genotype has spooked investors. Baird wasted little time in adjusting its outlook, cutting the price target in half to $5 (57% upside).</li><li>Achillion's odalasvir, an NS5A inhibitor, is being developed by J&amp;J's Janssen Pharmaceuticals under a May 2015 global agreement.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3258865-triple-combo-simeprevir-odalasvir-alminus-335-produced-100-percent-cure-rate-little-six-weeks\" target=\"_blank\">Triple combo of simeprevir, odalasvir and AL-335 produced 100% cure rate in as little as six weeks in mid-stage HCV study</a> (April 24)</li></ul><div class=\"tiny-share-widget\" data-id=\"3259046\" data-linked=\"Disappointing mid-stage data for triple combo for HCV-3 sinks Achillion; shares down 12%\" data-tweet=\"$ACHN - Disappointing mid-stage data for triple combo for HCV-3 sinks Achillion; shares down 12% https://seekingalpha.com/news/3259046-disappointing-mid-stage-data-for-triple-combo-for-hcvminus-3-sinks-achillion-shares-down-12?source=tweet\" data-url=\"https://seekingalpha.com/news/3259046-disappointing-mid-stage-data-for-triple-combo-for-hcvminus-3-sinks-achillion-shares-down-12\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:48 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>15&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3259041\" data-ts=\"1493062739\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/OCN\" target=\"_blank\">OCN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3259041-fitch-and-moodys-warn-on-ocwen\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Fitch and Moody&#39;s warn on Ocwen</a></h4><ul><li>Moody's earlier today said it could cut Ocwen Financial's (<a href='https://seekingalpha.com/symbol/OCN' title='Ocwen Financial Corporation'>OCN</a> <font color='red'>-6%</font>) credit rating thanks to last week's CFPB lawsuit and cease and desist orders from a number of states (which Hawaii has also joined).</li><li>Now Fitch has warned the same. S&amp;P cut late last week.</li><li>Up for cuts, though, is Ocwen's corporate credit rating, not its servicer rating. Were the servicer rating to be cut, that could be more ominous for Ocwen's subservicing deal with New Residential (<a href='https://seekingalpha.com/symbol/NRZ' title='New Residential Investment Corp.'>NRZ</a> <font color='red'>-0.6%</font>).</li><li>Altisource Portfolio Solutions (<a href='https://seekingalpha.com/symbol/ASPS' title='Altisource Portfolio Solutions SA'>ASPS</a> <font color='red'>-4.4%</font>)</li></ul><div class=\"tiny-share-widget\" data-id=\"3259041\" data-linked=\"Fitch and Moody&#39;s warn on Ocwen\" data-tweet=\"$OCN $OCN $NRZ - Fitch and Moody&#39;s warn on Ocwen https://seekingalpha.com/news/3259041-fitch-and-moodys-warn-on-ocwen?source=tweet\" data-url=\"https://seekingalpha.com/news/3259041-fitch-and-moodys-warn-on-ocwen\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:38 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>25&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3259039\" data-ts=\"1493062439\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/APFH\" target=\"_blank\">APFH</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3259039-new-high-for-advancepierre-foods\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">New high for AdvancePierre Foods</a></h4><ul> <li>AdvancePierre Foods (<a href='https://seekingalpha.com/symbol/APFH' title='AdvancePierre Foods Holdings'>APFH</a> <font color='green'>+5.6%</font>)&nbsp;<font color='green'>jumps another 5.64%</font> as last week's takeover buzz continues to bring in new buyers.</li> <li>The food company was mentioned on the FT Alphaville blog as a potential M&amp;A target.</li> <li>Shares of AdvancePierre reached an all-time high of $36.93 earlier.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3259039\" data-linked=\"New high for AdvancePierre Foods\" data-tweet=\"$APFH - New high for AdvancePierre Foods https://seekingalpha.com/news/3259039-new-high-for-advancepierre-foods?source=tweet\" data-url=\"https://seekingalpha.com/news/3259039-new-high-for-advancepierre-foods\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:33 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3259037\" data-ts=\"1493062157\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/EHTH\" target=\"_blank\">EHTH</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3259037-ceo-says-ehealth-on-track-to-meet-years-guidance\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">CEO says eHealth on track to meet year&#39;s guidance</a></h4><ul><li>in an interview, Scott Flanders, CEO of eHealth (<a href='https://seekingalpha.com/symbol/EHTH' title='eHealth, Inc.'>EHTH</a> <font color='green'>+3.2%</font>) says the private health insurance exchange operator is \"on track\" to meet its 2017 outlook. The company will report Q1 results on Thursday, April 27.</li><li><strong>2017 Guidance</strong> (released on Feb. 24): Total revenues: $165M - 175M; Medicare revenue: $91.5M - 96.5M; Individual/Family/Small Business revenue: $73.5M - 78.5M; Non-GAAP EBITDA: Loss of 16.1M - 14.1M; Non-GAAP loss/share: ($14.1M - 16.1M).</li><li>He adds that the company will start selling more short-term non-ACA-compliant plans due to the escalation in premiums. It is working on customized products that eHealth may even underwrite itself over time. Mr. Flanders states that the ACA or Obamacare, is \"imploding\" and \"repealing itself.\"</li><li>Insurers have complained that people have gamed the system by delaying buying coverage until they are sick. A few weeks ago, the Trump administration finalized rules aimed at stabilizing the market.</li><li>Bloomberg Intelligence's Jason McGorman says Anthem (<a href='https://seekingalpha.com/symbol/ANTM' title='Anthem, Inc.'>ANTM</a> <font color='green'>+0.5%</font>) has the largest financial exposure tied to ACA exchanges, followed by Cigna (<a href='https://seekingalpha.com/symbol/CI' title='Cigna Corporation'>CI</a> <font color='green'>+0.7%</font>), Molina (<a href='https://seekingalpha.com/symbol/MOH' title='Molina Healthcare, Inc.'>MOH</a> <font color='green'>+1.3%</font>) and Centene (<a href='https://seekingalpha.com/symbol/CNC' title='Centene Corporation'>CNC</a> <font color='green'>+2.1%</font>).</li><li>Source: Bloomberg</li></ul><div class=\"tiny-share-widget\" data-id=\"3259037\" data-linked=\"CEO says eHealth on track to meet year&#39;s guidance\" data-tweet=\"$EHTH $EHTH $ANTM - CEO says eHealth on track to meet year&#39;s guidance https://seekingalpha.com/news/3259037-ceo-says-ehealth-on-track-to-meet-years-guidance?source=tweet\" data-url=\"https://seekingalpha.com/news/3259037-ceo-says-ehealth-on-track-to-meet-years-guidance\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:29 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3259034\" data-ts=\"1493060450\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3259034-technology-top-gainers-losers-of-3-00-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Technology - Top Gainers / Losers as of 3:00 pm</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/LRAD' title='LRAD Corp'>LRAD</a> <font color='green'>+15%</font>. <a href='https://seekingalpha.com/symbol/UPLD' title='Upland Software'>UPLD</a> <font color='green'>+14%</font>. <a href='https://seekingalpha.com/symbol/MITK' title='Mitek Systems Inc.'>MITK</a> <font color='green'>+12%</font>. <a href='https://seekingalpha.com/symbol/SYX' title='Systemax Inc.'>SYX</a> <font color='green'>+9%</font>. <a href='https://seekingalpha.com/symbol/GSAT' title='Globalstar, Inc.'>GSAT</a> <font color='green'>+7%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/DRWI' title='DragonWave Inc.'>DRWI</a> <font color='red'>-10%</font>. <a href='https://seekingalpha.com/symbol/LTRX' title='Lantronix, Inc.'>LTRX</a> <font color='red'>-10%</font>. <a href='https://seekingalpha.com/symbol/NIHD' title='NII Holdings, Inc.'>NIHD</a> <font color='red'>-10%</font>. <a href='https://seekingalpha.com/symbol/MOSY' title='MoSys, Inc.'>MOSY</a> <font color='red'>-8%</font>. <a href='https://seekingalpha.com/symbol/COUP' title='Coupa Software Inc'>COUP</a> <font color='red'>-6%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3259034\" data-linked=\"Technology - Top Gainers / Losers as of 3:00 pm\" data-tweet=\"$GNSS $UPLD $MITK - Technology - Top Gainers / Losers as of 3:00 pm https://seekingalpha.com/news/3259034-technology-top-gainers-losers-of-3-00-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3259034-technology-top-gainers-losers-of-3-00-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:00 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>9&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3259031\" data-ts=\"1493060204\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/S\" target=\"_blank\">S</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3259031-sprint-opening-79-new-texas-stores-this-year\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Sprint opening 79 new Texas stores this year</a></h4><ul>   <li>Sprint (<a href=\"http://seekingalpha.com/symbol/S\" target=\"_blank\">S</a> <font color='green'>+2.8%</font>) says it's going to open <a href=\"https://seekingalpha.com/pr/16807708-sprint-expands-texas-79-new-retail-stores-creating-550-jobs\" target=\"_blank\">79 new retail stores in Texas</a> by the end of the year, its biggest expansion in the state since its launch of Sprint PCS stores 20 years ago.</li>    <li>That will mean more than 550 new jobs, it says, including retail, operations and technical experts.</li>    <li>The company currently operates nearly 350 locations in Texas.</li>    <li>It also says it's making network improvements in the state, noting that wireless data usage has grown more than 700% on average over the past five years in Austin, Dallas, Houston and Eastern Texas. It's enhanced coverage at Houston's NRG Stadium by 500% and added three-channel carrier aggregation around Houston.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3259031\" data-linked=\"Sprint opening 79 new Texas stores this year\" data-tweet=\"$S - Sprint opening 79 new Texas stores this year https://seekingalpha.com/news/3259031-sprint-opening-79-new-texas-stores-this-year?source=tweet\" data-url=\"https://seekingalpha.com/news/3259031-sprint-opening-79-new-texas-stores-this-year\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:56 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>211&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3259026\" data-ts=\"1493057234\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BDX\" target=\"_blank\">BDX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3259026-medical-tech-on-move-after-c-r-bard-sale\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Medical tech on the move after C.R. Bard sale</a></h4><ul><li>With Becton Dickinson (<a href='https://seekingalpha.com/symbol/BDX' title='Becton, Dickinson and Company'>BDX</a> <font color='red'>-3.3%</font>) agreeing to pay $24B for C.R. Bard (<a href='https://seekingalpha.com/symbol/BCR' title='C. R. Bard, Inc.'>BCR</a> <font color='green'>+20.2%</font>), investors are mulling other potential medical technology targets. Among them: Smith &amp; Nephew (<a href='https://seekingalpha.com/symbol/SNN' title='Smith & Nephew plc'>SNN</a> <font color='green'>+1.8%</font>), Agilent (<a href='https://seekingalpha.com/symbol/A' title='Agilent Technologies Inc.'>A</a> <font color='green'>+2.2%</font>), Baxter (<a href='https://seekingalpha.com/symbol/BAX' title='Baxter International Inc'>BAX</a> <font color='green'>+1.1%</font>), Wright Medical (<a href='https://seekingalpha.com/symbol/WMGI' title='Wright Medical Group, Inc.'>WMGI</a> <font color='green'>+0.7%</font>), Qiagen (<a href='https://seekingalpha.com/symbol/QGEN' title='Qiagen N.V.'>QGEN</a> <font color='green'>+2.2%</font>), GenMark Diagnostics (<a href='https://seekingalpha.com/symbol/GNMK' title='GenMark Diagnostics, Inc.'>GNMK</a> <font color='red'>-0.4%</font>), Globus Medical (<a href='https://seekingalpha.com/symbol/GMED' title='Globus Medical'>GMED</a> <font color='red'>-0.6%</font>), Illumina (<a href='https://seekingalpha.com/symbol/ILMN' title='Illumina, Inc.'>ILMN</a> <font color='green'>+2.5%</font>), Intuitive Surgical (<a href='https://seekingalpha.com/symbol/ISRG' title='Intuitive Surgical, Inc.'>ISRG</a> <font color='green'>+0.9%</font>), Waters (<a href='https://seekingalpha.com/symbol/WAT' title='Waters Corporation'>WAT</a> <font color='green'>+1.3%</font>), Cardiovascular Systems (<a href='https://seekingalpha.com/symbol/CSII' title='Cardiovascular Systems, Inc.'>CSII</a> <font color='green'>+2.2%</font>).</li><li>Turning back to the deal at hand, <a href=\"https://www.bloomberg.com/gadfly/articles/2017-04-24/becton-dickinson-s-24-billion-megadeal-won-t-bite\" target=\"_blank\">Bloomberg's Tara Lachapelle reminds</a> that this isn't Becton CEO Vincent Forlenza's first rodeo. Forlenza and team have delivered better-than-expected synergies on the 2015 CareFusion purchase.</li><li>And please don't call Forlenza a serial dealmaker in the mold of Valeant management. Yes, Becton is growing through acquisitions, but the deals thus far are valued-added for long-term owners, rather than temporary growth bursts.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3258828-becton-dickinson-buying-c-r-bard-24b\" target=\"_blank\">Becton Dickinson buying C.R. Bard for $24B</a> (April 23)</li></ul><div class=\"tiny-share-widget\" data-id=\"3259026\" data-linked=\"Medical tech on the move after C.R. Bard sale\" data-tweet=\"$BDX $BDX $BCR - Medical tech on the move after C.R. Bard sale https://seekingalpha.com/news/3259026-medical-tech-on-move-after-c-r-bard-sale?source=tweet\" data-url=\"https://seekingalpha.com/news/3259026-medical-tech-on-move-after-c-r-bard-sale\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:07 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3259023\" data-ts=\"1493056896\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3259023-energy-materials-top-gainers-losers-of-2-00-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Energy/Materials - Top Gainers / Losers as of 2:00 pm</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/DELT' title='Delta Technology Holdings Limited'>DELT</a> <font color='green'>+21%</font>. <a href='https://seekingalpha.com/symbol/GPRK' title='GeoPark Ltd.'>GPRK</a> <font color='green'>+10%</font>. <a href='https://seekingalpha.com/symbol/ZN' title='Zion Oil & Gas Inc'>ZN</a> <font color='green'>+7%</font>. <a href='https://seekingalpha.com/symbol/WG' title='Willbros Group, Inc.'>WG</a> <font color='green'>+6%</font>. <a href='https://seekingalpha.com/symbol/RYAM' title='Rayonier Advanced Materials'>RYAM</a> <font color='green'>+5%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/TRCH' title='Torchlight Energy Resources, Inc.'>TRCH</a> <font color='red'>-16%</font>. <a href='https://seekingalpha.com/symbol/CCLP' title='CSI Compressco LP'>CCLP</a> <font color='red'>-15%</font>. <a href='https://seekingalpha.com/symbol/HLX' title='Helix Energy Solutions Group, Inc.'>HLX</a> <font color='red'>-12%</font>. <a href='https://seekingalpha.com/symbol/NADL' title='North Atlantic Drilling Ltd.'>NADL</a> <font color='red'>-8%</font>. <a href='https://seekingalpha.com/symbol/SBGL' title='Sibanye-Stillwater'>SBGL</a> <font color='red'>-6%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3259023\" data-linked=\"Energy/Materials - Top Gainers / Losers as of 2:00 pm\" data-tweet=\"$DELT-OLD $GPRK $ZN - Energy/Materials - Top Gainers / Losers as of 2:00 pm https://seekingalpha.com/news/3259023-energy-materials-top-gainers-losers-of-2-00-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3259023-energy-materials-top-gainers-losers-of-2-00-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:01 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3259022\" data-ts=\"1493056496\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/RCKY\" target=\"_blank\">RCKY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3259022-rocky-brands-keeps-on-rolling\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Rocky Brands keeps on rolling</a></h4><ul> <li>Rocky Brands (NASDAQ:<a href='https://seekingalpha.com/symbol/RCKY' title='Rocky Brands, Inc.'>RCKY</a>) is <font color='green'>up another 9.67%</font> and hit a new 52-week high of $13.20 as the post-earnings rally extends.</li> <li>During the conference call last Friday, CEO Mike Brooks said the company's military segment has $40M in contract orders scheduled for delivery and sees opportunities next year and beyond.</li> <li><a href=\"https://seekingalpha.com/article/4063970-rocky-brands-rcky-ceo-mike-brooks-q1-2017-results-earnings-call-transcript?part=single\" target=\"_blank\">Rocky Brands earnings call transcript</a></li><li>Previously: <a href=\"https://seekingalpha.com/news/3258758-post-earnings-rip-rocky-brands\" target=\"_blank\">Post-earnings rip for Rocky Brands</a> (April 21)</li><li>Previously: <a href=\"https://seekingalpha.com/news/3258449-rocky-brands-beats-0_06-misses-revenue\" target=\"_blank\">Rocky Brands beats by $0.06, misses on revenue</a> (April 20)</li> <li>Wall Street analysts are pretty quiet on Rocky Brands, but Seeking Alpha has both <a href=\"https://seekingalpha.com/symbol/RCKY/focus\" target=\"_blank\">bullish and bearish takes</a> on the retailer.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3259022\" data-linked=\"Rocky Brands keeps on rolling\" data-tweet=\"$RCKY - Rocky Brands keeps on rolling https://seekingalpha.com/news/3259022-rocky-brands-keeps-on-rolling?source=tweet\" data-url=\"https://seekingalpha.com/news/3259022-rocky-brands-keeps-on-rolling\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:54 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3259018\" data-ts=\"1493055601\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SFM\" target=\"_blank\">SFM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3259018-sprouts-farmers-market-jolted-albertsons-whole-foods-news\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Sprouts Farmers Market jolted by Albertsons-Whole Foods news</a></h4><ul><li>Sprouts Farmers Market (<a href='https://seekingalpha.com/symbol/SFM' title='Sprouts Farmers Market'>SFM</a> <font color='red'>-3%</font>) is down sharply after Financial Times reports that Albertsons and Whole Foods have <a href=\"https://seekingalpha.com/news/3259016-whole-foods-spikes-talk-albertsons-interest\" target=\"_blank\">held talks</a>.</li><li>Last month it was Sprouts that appeared to be on the radar of the Cerberus-controlled company.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3252113-albertsons-considers-merger-sprouts\" target=\"_blank\">Albertsons considers merger with Sprouts</a> (March 20)</li><li>Previously: <a href=\"https://seekingalpha.com/news/3252234-sprouts-bidding-war-may-ensue-jefferies-says-maintains-buy-rating\" target=\"_blank\">Sprouts bidding war may ensue, Jefferies says as it maintains Buy rating</a> (March 20)</li></ul><div class=\"tiny-share-widget\" data-id=\"3259018\" data-linked=\"Sprouts Farmers Market jolted by Albertsons-Whole Foods news\" data-tweet=\"$SFM - Sprouts Farmers Market jolted by Albertsons-Whole Foods news https://seekingalpha.com/news/3259018-sprouts-farmers-market-jolted-albertsons-whole-foods-news?source=tweet\" data-url=\"https://seekingalpha.com/news/3259018-sprouts-farmers-market-jolted-albertsons-whole-foods-news\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:40 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3259016\" data-ts=\"1493055400\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ABS\" target=\"_blank\">ABS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3259016-whole-foods-spikes-on-talk-of-albertsons-interest\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Whole Foods spikes on talk of Albertsons interest</a></h4><ul> <li>Albertsons (NYSE:<a href='https://seekingalpha.com/symbol/ABS' title='Albertsons Companies'>ABS</a>) is exploring a <a href=\"https://www.ft.com/content/045caddc-290d-11e7-9ec8-168383da43b7\" target=\"_blank\">bid</a> for Whole Foods (WFM <font color='green'>+4%</font>), according to Financial Times.</li> <li>Sources indicate that the two companies have held preliminary talks, but no formal offer is on the table.</li> <li>Whole Foods has Evercore Partners in the house advising it on strategy.</li> <li>Albertsons is controlled by PE firm Cerberus Group. The grocery store chain has been on the IPO watch list for a couple of years.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3259016\" data-linked=\"Whole Foods spikes on talk of Albertsons interest\" data-tweet=\"$ABS $ABS $AMZN - Whole Foods spikes on talk of Albertsons interest https://seekingalpha.com/news/3259016-whole-foods-spikes-on-talk-of-albertsons-interest?source=tweet\" data-url=\"https://seekingalpha.com/news/3259016-whole-foods-spikes-on-talk-of-albertsons-interest\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:36 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>26&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3259013\" data-ts=\"1493054698\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/REED\" target=\"_blank\">REED</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3259013-reeds-ceo-exits-after-2016-and-preliminary-q1-numbers-shares-down-15\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Reed&#39;s CEO exits after 2016 and preliminary Q1 numbers; shares down 15%</a></h4><ul><li><a href=\"https://seekingalpha.com/pr/16807903-reeds-inc-announces-2016-financial-results-chris-reed-takes-new-role-chief-innovation-officer\" target=\"_blank\">Preliminary Q1 revenue</a> is seen at $8.3M vs. $10M a year ago, with lower sales volume having an impact on both gross and operating margins.</li><li>Full-year 2016 results <a href=\"https://seekingalpha.com/news/3259003-reeds-misses-0_17-misses-revenue\" target=\"_blank\">were also released</a>, and missed estimates.</li><li><a href=\"https://seekingalpha.com/pr/16807905-reeds-inc-announces-stefan-freeman-interim-ceo\" target=\"_blank\">CEO Chris Reed resigns</a>, to be replaced on an interim basis by board member Stefan Freeman. Reed will remain on the board, and also start in the newly created position of Chief Innovation Officer.</li><li>The company <a href=\"https://seekingalpha.com/pr/16807906-reeds-inc-announces-3_4-million-financing-transaction\" target=\"_blank\">also raised $3.4M</a> in a private placement of secured convertible subordinated paper, along with a warrant to buy 1.4M shares. The note bears interest of 12% per year. The warrants have a 5-year term and a strike price of $4.</li><li>A <a href=\"http://www.reedsinc.com\" target=\"_blank\">conference call</a> is set for 1:30 ET.</li><li><a href='https://seekingalpha.com/symbol/REED' title='Reed&#39;s, Inc.'>REED</a>&nbsp;<font color='red'>-14.75%</font></li></ul><div class=\"tiny-share-widget\" data-id=\"3259013\" data-linked=\"Reed&#39;s CEO exits after 2016 and preliminary Q1 numbers; shares down 15%\" data-tweet=\"$REED - Reed&#39;s CEO exits after 2016 and preliminary Q1 numbers; shares down 15% https://seekingalpha.com/news/3259013-reeds-ceo-exits-after-2016-and-preliminary-q1-numbers-shares-down-15?source=tweet\" data-url=\"https://seekingalpha.com/news/3259013-reeds-ceo-exits-after-2016-and-preliminary-q1-numbers-shares-down-15\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:24 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3259010\" data-ts=\"1493054147\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/UPLD\" target=\"_blank\">UPLD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3259010-upland-software-announces-acquisition-raises-2017-guidance-sharesplus-12\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Upland Software announces acquisition; raises 2017 guidance; Shares +12%</a></h4><ul>     <li>Upland Software (<a href='https://seekingalpha.com/symbol/UPLD' title='Upland Software'>UPLD</a> <font color='green'>+12.7%</font>) <a href=\"https://seekingalpha.com/pr/16807556-upland-software-announces-acquisition-raises-2017-guidance-raises-adjusted-ebitda-margin\" target=\"_blank\">announced</a> that it has acquired RightAnswers, Inc., an cloud-based knowledge management system. The transaction includes $17.2M in cash at closing, net of cash acquired, and a $2.5M cash holdback payable in one year (Indemnification claims, if any).</li>     <li>CEO Jack McDonald: \"We are pleased to welcome RightAnswers and their valued customers and partners to Upland, This strategic acquisition is a great product addition for current Upland customers looking to enhance their customer service, IT support, and enterprise-wide collaboration capabilities.\"</li>     <li><em>Business Outlook;&nbsp;</em>Upland raised its revenue, recurring revenue, and Adjusted EBITDA guidance ranges.</li>     <li>For the full year ending Dec. 31, 2017, Upland now expects to report total revenue to be in the range of $87.0 - $91.0M including recurring revenue in the range of $76.0 to $79.0M (+19% Y/Y). Adjusted EBITDA is expected to be in the range of $26.0 to $29.0M, for an Adjusted EBITDA margin of 31% at the mid-point, representing growth of 118% (Y/Y).</li>     <li>\"We are today raising our long-term Adjusted EBITDA margin target to 40% (from 35%) to reflect the increased customer loyalty and operating efficiency we are seeing with UplandOne and as we scale,\" said Mr. McDonald.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3259010\" data-linked=\"Upland Software announces acquisition; raises 2017 guidance; Shares +12%\" data-tweet=\"$UPLD - Upland Software announces acquisition; raises 2017 guidance; Shares +12% https://seekingalpha.com/news/3259010-upland-software-announces-acquisition-raises-2017-guidance-sharesplus-12?source=tweet\" data-url=\"https://seekingalpha.com/news/3259010-upland-software-announces-acquisition-raises-2017-guidance-sharesplus-12\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:15 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3259009\" data-ts=\"1493054145\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AKTX\" target=\"_blank\">AKTX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3259009-investors-sell-news-on-akari-coversin-data-alexion-gains\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Investors sell the news on Akari Coversin data; Alexion gains</a></h4><ul><li>Four patients who remain on Coversin <a href=\"https://seekingalpha.com/pr/16807108-akari-therapeutics-demonstrates-positive-response-coversin-ongoing-phase-2-pnh-trial\" target=\"_blank\">have seen LDH reductions</a> 1.3, 1.4, 1.5, and 1.8x the upper limit of normal, according to Akari (<a href='https://seekingalpha.com/symbol/AKTX' title='Akari Therapeutics Plc'>AKTX</a> <font color='red'>-10.7%</font>).</li><li>The primary endpoint of the Phase 2 trial is reduction in serum LDH to 1.8x ULN times or less.</li><li>Chardan's Madhu Kumar says the efficacy is inferior to Alexion's (<a href='https://seekingalpha.com/symbol/ALXN' title='Alexion Pharmaceuticals, Inc.'>ALXN</a> <font color='green'>+2.1%</font>) Soliris, noting it achieved LDH suppression down to 1.5x the ULN in 10 out 11 patients in a Phase 3 trial.</li><li>Even with today's decline, Akari is still nearly a three-bagger over the last month.</li></ul><div class=\"tiny-share-widget\" data-id=\"3259009\" data-linked=\"Investors sell the news on Akari Coversin data; Alexion gains\" data-tweet=\"$AKTX $AKTX $ALXN - Investors sell the news on Akari Coversin data; Alexion gains https://seekingalpha.com/news/3259009-investors-sell-news-on-akari-coversin-data-alexion-gains?source=tweet\" data-url=\"https://seekingalpha.com/news/3259009-investors-sell-news-on-akari-coversin-data-alexion-gains\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:15 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3259008\" data-ts=\"1493053771\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TEF\" target=\"_blank\">TEF</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3259008-bloomberg-telefonica-considering-ipo-for-o2-end-of-year\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Bloomberg: Telefonica considering IPO for O2 by end of year</a></h4><ul>   <li>Telefonica (<a href=\"http://seekingalpha.com/symbol/TEF\" target=\"_blank\">TEF</a> <font color='green'>+4.1%</font>) is looking at floating UK wireless unit O2 in an initial public offering <a href=\"https://www.bloomberg.com/news/articles/2017-04-24/telefonica-said-to-weigh-ipo-for-u-k-s-o2-as-soon-as-year-end\" target=\"_blank\">as soon as the end of the year</a>, Bloomberg reports.</li>    <li>It would be the latest in a series of moves Telefonica is considering to cut what is currently about $53B in debt.</li>    <li>Telefonica could sell a minority stake to the public in Q4, or elect to sell it to another bidder instead, sources told Bloomberg.</li>    <li>Previous plans for O2 were dealt delays, not only from the UK's decision to exit the EU, but also earlier from a regulatory block on a sale to Hutchison's Three UK.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3259008\" data-linked=\"Bloomberg: Telefonica considering IPO for O2 by end of year\" data-tweet=\"$TEF - Bloomberg: Telefonica considering IPO for O2 by end of year https://seekingalpha.com/news/3259008-bloomberg-telefonica-considering-ipo-for-o2-end-of-year?source=tweet\" data-url=\"https://seekingalpha.com/news/3259008-bloomberg-telefonica-considering-ipo-for-o2-end-of-year\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:09 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3259006\" data-ts=\"1493053520\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3259006-financials-top-5-gainers-losers-of-1-05-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Financials - Top 5 Gainers / Losers as of 1:05 PM</a></h4><ul><li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/DB' title='Deutsche Bank AG'>DB</a> <font color='green'>+12%</font>. <a href='https://seekingalpha.com/symbol/OPB' title='Opus Bank'>OPB</a> <font color='green'>+9%</font>.<a href='https://seekingalpha.com/symbol/BBVA' title='Banco Bilbao Vizcaya Argentaria, S.A.'>BBVA</a> <font color='green'>+8%</font>. <a href='https://seekingalpha.com/symbol/FCH' title='FelCor Lodging Trust'>FCH</a> <font color='green'>+8%</font>. <a href='https://seekingalpha.com/symbol/ING' title='ING Groep N.V.'>ING</a> <font color='green'>+7%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/GABC' title='German American Bancorp, Inc.'>GABC</a> <font color='red'>-31%</font>. <a href='https://seekingalpha.com/symbol/YIN' title='Yintech Investment Holdings'>YIN</a> <font color='red'>-12%</font>. <a href='https://seekingalpha.com/symbol/ICBK' title='County Bancorp'>ICBK</a> <font color='red'>-9%</font>. <a href='https://seekingalpha.com/symbol/OCN' title='Ocwen Financial Corporation'>OCN</a> <font color='red'>-7%</font>. <a href='https://seekingalpha.com/symbol/RLJ' title='RLJ Lodging Trust'>RLJ</a> <font color='red'>-6%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3259006\" data-linked=\"Financials - Top 5 Gainers / Losers as of 1:05 PM\" data-tweet=\"$DB $OPB $BBVA - Financials - Top 5 Gainers / Losers as of 1:05 PM https://seekingalpha.com/news/3259006-financials-top-5-gainers-losers-of-1-05-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3259006-financials-top-5-gainers-losers-of-1-05-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:05 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3259005\" data-ts=\"1493053518\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AKRX\" target=\"_blank\">AKRX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3259005-fresenius-near-deal-for-akorn-bloomberg\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Fresenius near deal for Akorn - Bloomberg</a></h4><ul><li>The deal would value Akorn (NASDAQ:<a href='https://seekingalpha.com/symbol/AKRX' title='Akorn, Inc.'>AKRX</a>) at $33-$35 per share, according to the report.</li><li>AKRX is&nbsp;<font color='green'>up 0.4%&nbsp;</font>to $33.04 after earlier having been in the red on the session.</li><li>Fresenius (NYSE:<a href='https://seekingalpha.com/symbol/FMS' title='Fresenius Medical Care AG & Co. KGAA'>FMS</a>) is&nbsp;<font color='green'>higher by 2.9%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3259005\" data-linked=\"Fresenius near deal for Akorn - Bloomberg\" data-tweet=\"$AKRX $AKRX $FMS - Fresenius near deal for Akorn - Bloomberg https://seekingalpha.com/news/3259005-fresenius-near-deal-for-akorn-bloomberg?source=tweet\" data-url=\"https://seekingalpha.com/news/3259005-fresenius-near-deal-for-akorn-bloomberg\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:05 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>11&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3259000\" data-ts=\"1493052325\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3259000-midday-gainers-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Midday Gainers / Losers</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/OPTT' title='Ocean Power Technologies, Inc.'>OPTT</a> <font color='green'>+42%</font>. <a href='https://seekingalpha.com/symbol/RGSE' title='RGS Energy, Inc.'>RGSE</a> <font color='green'>+22%</font>. <a href='https://seekingalpha.com/symbol/SSKN' title='STRATA Skin Sciences, Inc'>SSKN</a> <font color='green'>+20%</font>. <a href='https://seekingalpha.com/symbol/BCR' title='C. R. Bard, Inc.'>BCR</a> <font color='green'>+20%</font>. <a href='https://seekingalpha.com/symbol/DELT' title='Delta Technology Holdings Limited'>DELT</a> <font color='green'>+16%</font>. <a href='https://seekingalpha.com/symbol/PZRX' title='PhaseRx'>PZRX</a> <font color='green'>+14%</font>. <a href='https://seekingalpha.com/symbol/FUEL' title='Rocket Fuel'>FUEL</a> <font color='green'>+14%</font>. <a href='https://seekingalpha.com/symbol/UPLD' title='Upland Software'>UPLD</a> <font color='green'>+12%</font>. <a href='https://seekingalpha.com/symbol/DB' title='Deutsche Bank AG'>DB</a> <font color='green'>+11%</font>. <a href='https://seekingalpha.com/symbol/TPB' title='Turning Point Brands'>TPB</a> <font color='green'>+11%</font>.</li><li><b>Losers:&nbsp;</b><a href='https://seekingalpha.com/symbol/CCLP' title='CSI Compressco LP'>CCLP</a> <font color='red'>-15%</font>. <a href='https://seekingalpha.com/symbol/ABAC-OLD' title='Renmin Tianli Group'>ABAC-OLD</a> <font color='red'>-15%</font>. <a href='https://seekingalpha.com/symbol/AMMA-OLD' title='Alliance MMA'>AMMA-OLD</a> <font color='red'>-13%</font>. <a href='https://seekingalpha.com/symbol/YIN' title='Yintech Investment Holdings'>YIN</a> <font color='red'>-12%</font>. <a href='https://seekingalpha.com/symbol/DRYS' title='DryShips Inc.'>DRYS</a> <font color='red'>-12%</font>. <a href='https://seekingalpha.com/symbol/TRCH' title='Torchlight Energy Resources, Inc.'>TRCH</a> <font color='red'>-11%</font>. <a href='https://seekingalpha.com/symbol/AKTX' title='Akari Therapeutics Plc'>AKTX</a> <font color='red'>-10%</font>. <a href='https://seekingalpha.com/symbol/LTRX' title='Lantronix, Inc.'>LTRX</a> <font color='red'>-10%</font>. <a href='https://seekingalpha.com/symbol/HLX' title='Helix Energy Solutions Group, Inc.'>HLX</a> <font color='red'>-10%</font>. <a href='https://seekingalpha.com/symbol/NIHD' title='NII Holdings, Inc.'>NIHD</a>&nbsp;<font color='red'>-9%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3259000\" data-linked=\"Midday Gainers / Losers\" data-tweet=\"$OPTT $RGSE $SSKN - Midday Gainers / Losers https://seekingalpha.com/news/3259000-midday-gainers-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3259000-midday-gainers-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:45 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3258995\" data-ts=\"1493050793\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SHLDQ\" target=\"_blank\">SHLDQ</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3258995-s-and-p-talks-retail-defaults\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">S&amp;P talks retail defaults</a></h4><ul>     <li>S&amp;P Global Market Intelligence&nbsp;posts a list of the public retailers seen with the highest risk of a credit default within a year.</li>     <li>Topping the S&amp;P list is Sears Holdings (SHLD <font color='red'>-3.5%</font>) with a 23.84% probability of default. DGSE Companies (<a href='https://seekingalpha.com/symbol/DGSE' title='DGSE Companies, Inc'>DGSE</a> <font color='red'>-1.2%</font>), Appliance Recycling Centers of America (<a href='https://seekingalpha.com/symbol/ARCI' title='Appliance Recycling Centers of America, Inc.'>ARCI</a> <font color='red'>-1.1%</font>), Bon-Ton Stores (<a href='https://seekingalpha.com/symbol/BONT' title='The Bon-Ton Stores, Inc.'>OTC:BONT</a> <font color='green'>+1.7%</font>) and Bebe Stores (<a href='https://seekingalpha.com/symbol/BEBE' title='bebe stores, inc.'>OTC:BEBE</a> <font color='red'>-0.8%</font>) are all assigned +10% odds of default. Destination XL Group (<a href='https://seekingalpha.com/symbol/DXLG' title='Destination XL Group, Inc.'>DXLG</a> <font color='green'>+0.7%</font>), Perfumania Holdings (<a href='https://seekingalpha.com/symbol/PERF' title='Perfumania Holdings, Inc'>PERF</a>), Fenix Parts (<a href='https://seekingalpha.com/symbol/FENX' title='Fenix Parts'>OTC:FENX</a> <font color='red'>-1.7%</font>), Tailored Brands (<a href='https://seekingalpha.com/symbol/TLRD' title='Tailored Brands, Inc'>TLRD</a> <font color='green'>+1.2%</font>) and Sears Hometown and Outlet Stores (<a href='https://seekingalpha.com/symbol/SHOS' title='Sears Hometown and Outlet Stores, Inc.'>SHOS</a> <font color='red'>-1.4%</font>) round out the top ten, with default probabilities ranging between 6.1% and 8.1%.</li>     <li>\"The convenience of online shopping, and the downward pressure it has put on pricing, has radically altered consumer behavior. Most shoppers now browse for value online, and the younger cohort of the prized millennial demographic, some of whom may never have developed a penchant for long afternoons at the mall, clearly prefers that channel,\" writes S&amp;P Global risk assessor Jim Elder in the report.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3258995\" data-linked=\"S&amp;P talks retail defaults\" data-tweet=\"$SHLDQ $SHLDQ $DGSE - S&amp;P talks retail defaults https://seekingalpha.com/news/3258995-s-and-p-talks-retail-defaults?source=tweet\" data-url=\"https://seekingalpha.com/news/3258995-s-and-p-talks-retail-defaults\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:19 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>46&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3258991\" data-ts=\"1493050175\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PZRX\" target=\"_blank\">PZRX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3258991-ema-tags-phaserxs-lead-product-candidate-orphan-drug-for-rare-enzyme-deficiency-disorder\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">EMA tags PhaseRx&#39;s lead product candidate an Orphan Drug for rare enzyme deficiency disorder; shares ahead 13%</a></h4><ul><li>Thinly traded nano cap PhaseRx (<a href='https://seekingalpha.com/symbol/PZRX' title='PhaseRx'>PZRX</a> <font color='green'>+12.9%</font>) is up on a 34x surge in volume in response to the <a href=\"http://ec.europa.eu/health/documents/community-register/html/o1867.htm\" target=\"_blank\">news </a>that the European Medicines Agency has designated lead product candidate PRX-OTC an Orphan Drug for the treatment of ornithine transcarbamylase deficiency, a rare inherited disorder that causes ammonia to accumulate in the blood.</li><li>IND-stage PRX-OTC is a therapeutic designed to deliver the mRNA encoding the missing enzyme into liver cells.</li><li>Among the benefits of Orphan Drug status in the EU is a 10-year period of market exclusivity for the indication, if approved.</li></ul><div class=\"tiny-share-widget\" data-id=\"3258991\" data-linked=\"EMA tags PhaseRx&#39;s lead product candidate an Orphan Drug for rare enzyme deficiency disorder; shares ahead 13%\" data-tweet=\"$PZRX - EMA tags PhaseRx&#39;s lead product candidate an Orphan Drug for rare enzyme deficiency disorder; shares ahead 13% https://seekingalpha.com/news/3258991-ema-tags-phaserxs-lead-product-candidate-orphan-drug-for-rare-enzyme-deficiency-disorder?source=tweet\" data-url=\"https://seekingalpha.com/news/3258991-ema-tags-phaserxs-lead-product-candidate-orphan-drug-for-rare-enzyme-deficiency-disorder\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:09 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3258992\" data-ts=\"1493049697\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3258992-consumer-top-gainers-losers-of-12-00-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Consumer - Top Gainers / Losers as of 12:00 pm</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/KNDI' title='Kandi Technologies Group, Inc.'>KNDI</a> <font color='green'>+9%</font>. <a href='https://seekingalpha.com/symbol/TPB' title='Turning Point Brands'>TPB</a> <font color='green'>+8%</font>. <a href='https://seekingalpha.com/symbol/HAS' title='Hasbro, Inc.'>HAS</a> <font color='green'>+6%</font>. <a href='https://seekingalpha.com/symbol/PRMW' title='Primo Water'>PRMW</a> <font color='green'>+6%</font>. AOI <font color='green'>+6%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/ABAC-OLD' title='Renmin Tianli Group'>ABAC-OLD</a> <font color='red'>-12%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3258992\" data-linked=\"Consumer - Top Gainers / Losers as of 12:00 pm\" data-tweet=\"$KNDI $TPB $HAS - Consumer - Top Gainers / Losers as of 12:00 pm https://seekingalpha.com/news/3258992-consumer-top-gainers-losers-of-12-00-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3258992-consumer-top-gainers-losers-of-12-00-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:01 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3258988\" data-ts=\"1493049261\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CYTR\" target=\"_blank\">CYTR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3258988-cytrx-continues-aldoxorubicin-stoked-up-move-shares-ahead-35\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">CytRx continues aldoxorubicin-stoked up move, shares ahead 35%</a></h4><ul><li>CytRX (<a href='https://seekingalpha.com/symbol/CYTR' title='CytRx Corporation'>CYTR</a> <font color='green'>+35.4%</font>) is up on more than a 12x surge in volume as investors continue to buy in based on the company's plan to file a U.S. marketing application seeking approval of aldoxorubicin for the treatment of soft tissue sarcoma. Shares have almost doubled since last week.</li><li>It intends to submit its application under the FDA's abbreviated 505(b)(2) pathway which allows the sponsor to include some data generated by others.</li><li>The company's late-stage study failed to achieve the primary endpoint, but a reanalysis showed a subset of patients in which aldoxorubicin worked better that investigator's choice of therapy with less risk.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3257843-fda-board-cytrxs-regulatory-plan-aldoxorubicin-nda-tap-q4-shares-ahead-32-percent-premarket\" target=\"_blank\">FDA on board with CytRx's regulatory plan for aldoxorubicin, NDA on tap for Q4; shares ahead 32% premarket</a> (April 19)</li><li>Previously: <a href=\"https://seekingalpha.com/news/3227257-scrubbed-data-failed-late-stage-study-show-treatment-effect-subset-patients-cytrxs\" target=\"_blank\">Scrubbed data from failed late-stage study show treatment effect in subset of patients for CytRx's aldoxorubicin; NDA planned for 2017</a> (Nov. 29, 2016)</li></ul><div class=\"tiny-share-widget\" data-id=\"3258988\" data-linked=\"CytRx continues aldoxorubicin-stoked up move, shares ahead 35%\" data-tweet=\"$CYTR - CytRx continues aldoxorubicin-stoked up move, shares ahead 35% https://seekingalpha.com/news/3258988-cytrx-continues-aldoxorubicin-stoked-up-move-shares-ahead-35?source=tweet\" data-url=\"https://seekingalpha.com/news/3258988-cytrx-continues-aldoxorubicin-stoked-up-move-shares-ahead-35\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:54 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>11&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3258982\" data-ts=\"1493047711\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FCH\" target=\"_blank\">FCH</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3258982-felcor-lodgingplus-6-on-sale-to-rlj-lodging\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">FelCor Lodging +6% on sale to RLJ Lodging</a></h4><ul><li>Under the terms, each share of FelCor Lodging (<a href='https://seekingalpha.com/symbol/FCH' title='FelCor Lodging Trust'>FCH</a> <font color='green'>+6.8%</font>) will be converted into 0.362 shares of RLJ Lodging (<a href='https://seekingalpha.com/symbol/RLJ' title='RLJ Lodging Trust'>RLJ</a> <font color='red'>-6.6%</font>), and following the deal, RLJ shareholders will own about 71% of the combined company.</li><li>The merged company will have an enterprise value of $7B, with 160 hotels in 26 states. The deal is seen as accretive in year one, with expected cash G&amp;A savings of about $12M, and roughly $10M of potential savings from stock-based compensation and capitalized cash G&amp;A.</li><li>The combined company is expected to pay a $0.33 quarterly dividend (same as RLJ now pays).</li><li>Closing is expected before year-end.</li><li>Source: <a href=\"https://seekingalpha.com/pr/16806991-rlj-lodging-trust-b-felcor-b-lodging-trust-merge-creating-7-billion-leading-lodging-reit\" target=\"_blank\">Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3258982\" data-linked=\"FelCor Lodging +6% on sale to RLJ Lodging\" data-tweet=\"$FCH $FCH $RLJ - FelCor Lodging +6% on sale to RLJ Lodging https://seekingalpha.com/news/3258982-felcor-lodgingplus-6-on-sale-to-rlj-lodging?source=tweet\" data-url=\"https://seekingalpha.com/news/3258982-felcor-lodgingplus-6-on-sale-to-rlj-lodging\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:28 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>17&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3258979\" data-ts=\"1493047140\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BWLD\" target=\"_blank\">BWLD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3258979-buffalo-wild-wings-defends\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Buffalo Wild Wings defends itself</a></h4><ul> <li>Buffalo Wild Wings (<a href='https://seekingalpha.com/symbol/BWLD' title='Buffalo Wild Wings, Inc.'>BWLD</a> <font color='green'>+1.7%</font>) asks shareholders to vote for its slate of nominees to the board in a letter posted today. Key portions of the defense are posted below.</li>     <li>\"Our       Board and management team are under attack from a short-term-focused       hedge fund, Marcato Capital Management, LP, that seeks to upend our       winning formula and business strategy.\"</li>     <li>\"We       believe that Marcato&rsquo;s plans for the business &ndash; involving a massive       refranchising of our company-owned stores, among other things &ndash; will not       create sustainable shareholder value but will create substantial risk.\"</li>     <li>\"Our earnings per share       have grown at a compounded annual rate of more than 18% over the last       ten years. Returns on the capital we have deployed in the business       exceed the returns generated by our peers on their capital and far       exceed our cost of capital.\"</li><li>Source: <a href=\"https://seekingalpha.com/pr/16807050-buffalo-wild-wings-files-definitive-proxy-materials\" target=\"_blank\">Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3258979\" data-linked=\"Buffalo Wild Wings defends itself\" data-tweet=\"$BWLD - Buffalo Wild Wings defends itself https://seekingalpha.com/news/3258979-buffalo-wild-wings-defends?source=tweet\" data-url=\"https://seekingalpha.com/news/3258979-buffalo-wild-wings-defends\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:19 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3258976\" data-ts=\"1493046838\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/JCP\" target=\"_blank\">JCP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3258976-j-c-penney-to-expand-sephora-presence\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">J.C. Penney to expand Sephora presence</a></h4><ul> <li>J.C. Penney (<a href='https://seekingalpha.com/symbol/JCP' title='J.C. Penney Company Inc.'>JCP</a> <font color='red'>-0.4%</font>) says it will add <a href=\"http://ir.jcpenney.com/phoenix.zhtml?c=70528&amp;p=irol-newscompany\" target=\"_blank\">70</a> new Sephora shops inside of its stores beginning next month.</li> <li>The company also plans to expand 32 existing Sephora shops by almost 50%.</li> <li>A new feature will allow customers to buy Sephora products online and pick them up in JCP stores on the same day.</li> <li>Sephora is owned by LVMH (<a href='https://seekingalpha.com/symbol/LVMHF' title='LVMH-Moet Hennessy Louis Vuitton'>OTCPK:LVMHF</a>, <a href='https://seekingalpha.com/symbol/LVMUY' title='LVMH-Moet Hennessy Louis Vuitton ADR'>OTCPK:LVMUY</a>).</li> </ul><div class=\"tiny-share-widget\" data-id=\"3258976\" data-linked=\"J.C. Penney to expand Sephora presence\" data-tweet=\"$JCP $JCP $LVMHF - J.C. Penney to expand Sephora presence https://seekingalpha.com/news/3258976-j-c-penney-to-expand-sephora-presence?source=tweet\" data-url=\"https://seekingalpha.com/news/3258976-j-c-penney-to-expand-sephora-presence\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:13 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3258975\" data-ts=\"1493046225\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NOK\" target=\"_blank\">NOK</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3258975-nokia-tender-for-comptel-reaches-nearly-97-of-shares\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Nokia tender for Comptel reaches nearly 97% of shares</a></h4><ul>   <li>Nokia Solutions and Networks (<a href=\"http://seekingalpha.com/symbol/NOK\" target=\"_blank\">NOK</a> <font color='green'>+3%</font>) has wrapped a subsequent offer period for the shares of Comptel with <a href=\"https://seekingalpha.com/pr/16806963-final-result-subsequent-offer-period-nokia-solutions-networks-tender-offer-shares-option\" target=\"_blank\">another 3.99% of shares tendered</a>.</li>    <li>That brings Nokia's total through the previous offer period and other market purchases to 96.95% of all shares, along with about 94.43% of Comptel's 2014 options rights.</li>    <li>It's filed for compulsory redemption for the remaining Comptel shares and intends to delist the stock as soon as legally permissible.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3258975\" data-linked=\"Nokia tender for Comptel reaches nearly 97% of shares\" data-tweet=\"$NOK - Nokia tender for Comptel reaches nearly 97% of shares https://seekingalpha.com/news/3258975-nokia-tender-for-comptel-reaches-nearly-97-of-shares?source=tweet\" data-url=\"https://seekingalpha.com/news/3258975-nokia-tender-for-comptel-reaches-nearly-97-of-shares\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:03 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3258957\" data-ts=\"1493046094\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3258957-healthcare-top-5-gainers-losers-of-11-00\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Healthcare - Top 5 Gainers / Losers as of 11:00 am</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/BCR' title='C. R. Bard, Inc.'>BCR</a> <font color='green'>+20%</font>. <a href='https://seekingalpha.com/symbol/SSKN' title='STRATA Skin Sciences, Inc'>SSKN</a> <font color='green'>+16%</font>. <a href='https://seekingalpha.com/symbol/PZRX' title='PhaseRx'>PZRX</a> <font color='green'>+15%</font>. <a href='https://seekingalpha.com/symbol/AKER' title='Akers Biosciences Inc.'>AKER</a> <font color='green'>+8%</font>. <a href='https://seekingalpha.com/symbol/SCYX' title='SCYNEXIS, Inc.'>SCYX</a> <font color='green'>+7%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/AKTX' title='Akari Therapeutics Plc'>AKTX</a> <font color='red'>-12%</font>. <a href='https://seekingalpha.com/symbol/XOMA' title='XOMA Corporation'>XOMA</a> <font color='red'>-11%</font>. <a href='https://seekingalpha.com/symbol/GNMX' title='Aevi Genomic Medicine, Inc.'>GNMX</a> <font color='red'>-10%</font>. <a href='https://seekingalpha.com/symbol/RVP' title='Retractable Technologies, Inc'>RVP</a> <font color='red'>-10%</font>. <a href='https://seekingalpha.com/symbol/EYEG' title='EyeGate Pharmaceuticals'>EYEG</a> <font color='red'>-7%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3258957\" data-linked=\"Healthcare - Top 5 Gainers / Losers as of 11:00 am\" data-tweet=\"$BCR $SSKN $PZRX - Healthcare - Top 5 Gainers / Losers as of 11:00 am https://seekingalpha.com/news/3258957-healthcare-top-5-gainers-losers-of-11-00?source=tweet\" data-url=\"https://seekingalpha.com/news/3258957-healthcare-top-5-gainers-losers-of-11-00\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:01 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3258970\" data-ts=\"1493045414\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/HAS\" target=\"_blank\">HAS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3258970-hasbro-passes-mattel-in-sales\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Hasbro passes Mattel in sales</a></h4><ul> <li>Hasbro (<a href='https://seekingalpha.com/symbol/HAS' title='Hasbro, Inc.'>HAS</a> <font color='green'>+5.2%</font>) passed Mattel (<a href='https://seekingalpha.com/symbol/MAT' title='Mattel, Inc.'>MAT</a> <font color='red'>-0.5%</font>) for quarterly revenue for the first time since 2000 after a surprising 10% jump in gaming revenue. Operating profit from the entertainment and licensing business more than doubled to $11M during the quarter.</li> <li>Stifel Nicolaus thinks the strong entertainment lineup for Habro this year will lead to more upward earnings revisions.</li> <li>Previously: <a href=\"https://seekingalpha.com/news/3258857-hasbro-beats-0_05-beats-revenue\" target=\"_blank\">Hasbro beats by $0.05, beats on revenue</a> (April 24)</li><li>Previously: <a href=\"https://seekingalpha.com/news/3258872-hasbro-positive-post-q1-results\" target=\"_blank\">Hasbro positive post Q1 results</a> (April 24)</li> <li>Sources: <a href=\"https://www.wsj.com/articles/BT-CO-20170424-706900\" target=\"_blank\">Wall Street Journal</a>, Bloomberg.</li><li>Shares of Hasbro carved out a new all-time high of $104.14 earlier before tracking back.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3258970\" data-linked=\"Hasbro passes Mattel in sales\" data-tweet=\"$HAS $HAS $MAT - Hasbro passes Mattel in sales https://seekingalpha.com/news/3258970-hasbro-passes-mattel-in-sales?source=tweet\" data-url=\"https://seekingalpha.com/news/3258970-hasbro-passes-mattel-in-sales\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:50 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3258969\" data-ts=\"1493045044\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/EAPH\" target=\"_blank\">EAPH</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3258969-easton-pharma-starts-talks-israeli-firm-over-possible-deal-shares-ahead-5\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Easton Pharma starts talks with Israeli firm over possible deal; shares ahead 5%</a></h4><ul><li>Thinly traded nano cap Eaton Pharmaceuticals (<a href='https://seekingalpha.com/symbol/EAPH' title='Easton Pharmaceuticals, Inc.'>OTCPK:EAPH</a> <font color='green'>+5.1%</font>) says it has signed a non-disclosure <a href=\"https://seekingalpha.com/pr/16807680-easton-pharmaceuticals-announces-signing-nda-starts-negotiations-acquisition\" target=\"_blank\">agreement</a> with Israel-based agricultural products developer ahead of negotiations over deal with the company. Potential transactions include an acquisition, joint venture or a distribution agreement.</li><li>The Israeli firm produces crop protection products that are based on extracts from local plants in the Judean Desert.</li></ul><div class=\"tiny-share-widget\" data-id=\"3258969\" data-linked=\"Easton Pharma starts talks with Israeli firm over possible deal; shares ahead 5%\" data-tweet=\"$EAPH - Easton Pharma starts talks with Israeli firm over possible deal; shares ahead 5% https://seekingalpha.com/news/3258969-easton-pharma-starts-talks-israeli-firm-over-possible-deal-shares-ahead-5?source=tweet\" data-url=\"https://seekingalpha.com/news/3258969-easton-pharma-starts-talks-israeli-firm-over-possible-deal-shares-ahead-5\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:44 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3258967\" data-ts=\"1493044436\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MSFT\" target=\"_blank\">MSFT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3258967-microsoft-using-linkedin-data-to-challenge-in-sales-software\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Microsoft using LinkedIn data to challenge in sales software</a></h4><ul>   <li>Microsoft (<a href=\"http://seekingalpha.com/symbol/MSFT\" target=\"_blank\">MSFT</a> <font color='green'>+1.6%</font>) is boosting its challenge to sales software leader Salesforce.com (<a href=\"http://seekingalpha.com/symbol/CRM\" target=\"_blank\">CRM</a> <font color='green'>+0.3%</font>) with the first major fruit borne by its $26B acquisition of LinkedIn.</li>    <li>Data from LinkedIn -- particularly a salesperson's relationships on the business-focused social network -- is <a href=\"http://www.reuters.com/article/us-microsoft-linkedin-idUSKBN17Q1FW\" target=\"_blank\">going into Microsoft's Dynamics 365</a>, and promises to offer ways to salvage an at-risk deal based on artificial intelligence.</li>    <li>\"I want to be able to democratize AI so that any customer using these products is able to, in fact, take their own data and load it into AI for themselves,\" says Microsoft chief Satya Nadella.</li>    <li>The company's a small player in sales software, but says specialized applications are Microsoft's \"third cloud,\" representing its future, he says.</li>    <li>The former chief of Dynamics said in 2015 that it was a $2B business unit, but Microsoft is fourth in sales software behind Salesforce.com, Oracle (<a href=\"http://seekingalpha.com/symbol/ORCL\" target=\"_blank\">ORCL</a> <font color='green'>+0.9%</font>) and SAP (<a href=\"http://seekingalpha.com/symbol/SAP\" target=\"_blank\">SAP</a> <font color='green'>+3.8%</font>).</li> </ul><div class=\"tiny-share-widget\" data-id=\"3258967\" data-linked=\"Microsoft using LinkedIn data to challenge in sales software\" data-tweet=\"$MSFT $MSFT $CRM - Microsoft using LinkedIn data to challenge in sales software https://seekingalpha.com/news/3258967-microsoft-using-linkedin-data-to-challenge-in-sales-software?source=tweet\" data-url=\"https://seekingalpha.com/news/3258967-microsoft-using-linkedin-data-to-challenge-in-sales-software\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:33 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>9&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3258964\" data-ts=\"1493044377\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/O\" target=\"_blank\">O</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3258964-rough-session-for-reits-low-rate-respite-ends\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Rough session for REITs as low-rate respite ends</a></h4><ul><li>A sizable whoosh down in longer-term interest rates over the past month had given some hope that perhaps the rate hike cycle was nearing an end, but the 10-year yield - as low as 2.16% at one point last week - has returned to north of 2.30% this morning.</li><li>Responsible for today's move is relief over the outcome of Sunday's French election, and European stocks are&nbsp;<font color='green'>ahead 2%</font>; the U.S. is&nbsp;<font color='green'>up 1%</font>.</li><li>The only sector in the red is the REITs (<a href='https://seekingalpha.com/symbol/IYR' title='iShares U.S. Real Estate ETF'>IYR</a> <font color='red'>-1.5%</font>), (<a href='https://seekingalpha.com/symbol/VNQ' title='Vanguard Real Estate ETF'>VNQ</a> <font color='red'>-1.8%</font>). Another income favorite, the utility sector (NYSEARCA:<a href='https://seekingalpha.com/symbol/XLU' title='Utilities Select Sector SPDR ETF'>XLU</a>) is flat.</li><li>Realty Income (<a href='https://seekingalpha.com/symbol/O' title='Realty Income Corporation'>O</a> <font color='red'>-2.7%</font>), Omega Healthcare (<a href='https://seekingalpha.com/symbol/OHI' title='Omega Healthcare Investors, Inc'>OHI</a> <font color='red'>-2.5%</font>), HCP (<a href='https://seekingalpha.com/symbol/HCP' title='HCP, Inc.'>HCP</a> <font color='red'>-3.3%</font>), Vereit (<a href='https://seekingalpha.com/symbol/VER' title='VEREIT Inc.'>VER</a> <font color='red'>-2.8%</font>), Essex Property (<a href='https://seekingalpha.com/symbol/ESS' title='Essex Property Trust, Inc.'>ESS</a> <font color='red'>-1.9%</font>), Simon Property (<a href='https://seekingalpha.com/symbol/SPG' title='Simon Property Group, Inc.'>SPG</a> <font color='red'>-2.4%</font>), Kimco (<a href='https://seekingalpha.com/symbol/KIM' title='Kimco Realty Corporation'>KIM</a> <font color='red'>-2.5%</font>), Public Storage (<a href='https://seekingalpha.com/symbol/PSA' title='Public Storage'>PSA</a> <font color='red'>-2.3%</font>), Government Properties (<a href='https://seekingalpha.com/symbol/GOV-OLD' title='Government Properties Income Trust'>GOV-OLD</a> <font color='red'>-2.1%</font>), Stag Industrial (<a href='https://seekingalpha.com/symbol/STAG' title='STAG Industrial, Inc.'>STAG</a> <font color='red'>-2%</font>)</li><li>ETFs: <a href='https://seekingalpha.com/symbol/VNQ' title='Vanguard Real Estate ETF'>VNQ</a>, <a href='https://seekingalpha.com/symbol/IYR' title='iShares U.S. Real Estate ETF'>IYR</a>, <a href='https://seekingalpha.com/symbol/DRN' title='Direxion Daily Real Estate Bull 3x Shares ETF'>DRN</a>, <a href='https://seekingalpha.com/symbol/RQI' title='Cohen&Steers Quality Income Realty Fund'>RQI</a>, <a href='https://seekingalpha.com/symbol/URE' title='ProShares Ultra Real Estate ETF'>URE</a>, <a href='https://seekingalpha.com/symbol/SCHH' title='Schwab U.S. REIT ETF'>SCHH</a>, <a href='https://seekingalpha.com/symbol/ICF' title='iShares Cohen & Steers REIT ETF'>ICF</a>, <a href='https://seekingalpha.com/symbol/RWR' title='SPDR Dow Jones REIT ETF'>RWR</a>, <a href='https://seekingalpha.com/symbol/SRS' title='ProShares UltraShort Real Estate ETF'>SRS</a>, <a href='https://seekingalpha.com/symbol/RNP' title='Cohen&Steers REIT&Preferred Income Fund'>RNP</a>, <a href='https://seekingalpha.com/symbol/RFI' title='Cohen&Steers Total Return Realty Fund'>RFI</a>, <a href='https://seekingalpha.com/symbol/JRS' title='Nuveen Real Estate Income Fund'>JRS</a>, <a href='https://seekingalpha.com/symbol/KBWY' title='Invesco KBW Premium Yield Equity REIT Portfolio ETF'>KBWY</a>, <a href='https://seekingalpha.com/symbol/NRO' title='Neuberger Berman Real Estate Securities Income Fund'>NRO</a>, <a href='https://seekingalpha.com/symbol/DRV' title='Direxion Daily Real Estate Bear 3x Shares ETF'>DRV</a>, <a href='https://seekingalpha.com/symbol/RIT' title='LMP Real Estate Income Fund'>RIT</a>, <a href='https://seekingalpha.com/symbol/RIF' title='RMR Real Estate Income Fund'>RIF</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3258964\" data-linked=\"Rough session for REITs as low-rate respite ends\" data-tweet=\"$O $IYR $VNQ - Rough session for REITs as low-rate respite ends https://seekingalpha.com/news/3258964-rough-session-for-reits-low-rate-respite-ends?source=tweet\" data-url=\"https://seekingalpha.com/news/3258964-rough-session-for-reits-low-rate-respite-ends\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:32 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>36&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3258958\" data-ts=\"1493042901\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ADMS\" target=\"_blank\">ADMS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3258958-pooled-late-stage-data-confirms-efficacy-of-adamas-pharmas-amantadine-in-parkinsons-shares\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Pooled late-stage data confirms efficacy of Adamas Pharma&#39;s amantadine in Parkinson&#39;s ; shares ahead 2%</a></h4><ul><li>Thinly traded micro cap Adamas Pharmaceuticals (<a href='https://seekingalpha.com/symbol/ADMS' title='Adamas Pharmaceuticals, Inc.'>ADMS</a> <font color='green'>+1.5%</font>) heads north on light volume on the heels of its <a href=\"https://seekingalpha.com/pr/16807548-adamas-presents-adsminus-5102-pooled-phase-3-data-confirming-statistically-significant\" target=\"_blank\">announcement </a>of pooled results from two Phase 3 clinical trials evaluating ADS-5102 (amantadine) in patients with Parkinson's disease &#40;PD&#41;. The data were presented at the American Academy of Neurology Annual Meeting in Boston.</li><li>Pooled results from the EASE LID and EASE LID 3 studies were consistent with the original results from the trials that showed treatment with ADS-5102 produced a statistically significantly reduction in OFF time and a significant reduction in levodopa-induced dyskinesia &#40;LID&#41;.</li><li><a href=\"http://www.adamaspharma.com/ads5102/\" target=\"_blank\">ADS-5102</a>&nbsp;is an extended-release formulation of PD drug&nbsp;<a href=\"https://en.wikipedia.org/wiki/Amantadine\" target=\"_blank\">amantadine</a>, originally approved by the FDA in November 2003 under the brand name Symmetrel, marketed by Endo Pharmaceuticals.</li><li>Adamas' U.S. marketing application is currently under FDA review with an action date of August 24.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3001486-adamas-pharmas-lead-product-candidate-successful-late-stage-lid-study-shares-43-percent\" target=\"_blank\">Adamas Pharma's lead product candidate successful in late-stage LID study; shares up 43% premarket</a> (Dec. 23, 2015)</li></ul><div class=\"tiny-share-widget\" data-id=\"3258958\" data-linked=\"Pooled late-stage data confirms efficacy of Adamas Pharma&#39;s amantadine in Parkinson&#39;s ; shares ahead 2%\" data-tweet=\"$ADMS - Pooled late-stage data confirms efficacy of Adamas Pharma&#39;s amantadine in Parkinson&#39;s ; shares ahead 2% https://seekingalpha.com/news/3258958-pooled-late-stage-data-confirms-efficacy-of-adamas-pharmas-amantadine-in-parkinsons-shares?source=tweet\" data-url=\"https://seekingalpha.com/news/3258958-pooled-late-stage-data-confirms-efficacy-of-adamas-pharmas-amantadine-in-parkinsons-shares\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:08 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3258959\" data-ts=\"1493042858\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PLYA\" target=\"_blank\">PLYA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3258959-deutsche-sees-breakout-for-playa-hotels-resorts\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Deutsche sees breakout for Playa Hotels &amp; Resorts</a></h4><ul> <li>Deutsche Bank starts off coverage on Playa Hotels &amp; Resorts (<a href='https://seekingalpha.com/symbol/PLYA' title='Playa Hotels & Resorts'>PLYA</a> <font color='green'>+0.8%</font>) with a Buy rating.</li> <li>The investment firm sets a price target of $14 on the resort operator. Nomura is the only other major house with a rating out on Playa (Buy, $13 PT).</li> <li>Playa has traded in a range of $9.45 to $12.00 since debuting on the market last month. The company is due to report earnings on May 8.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3258959\" data-linked=\"Deutsche sees breakout for Playa Hotels &amp; Resorts\" data-tweet=\"$PLYA - Deutsche sees breakout for Playa Hotels &amp; Resorts https://seekingalpha.com/news/3258959-deutsche-sees-breakout-for-playa-hotels-resorts?source=tweet\" data-url=\"https://seekingalpha.com/news/3258959-deutsche-sees-breakout-for-playa-hotels-resorts\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:07 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3258956\" data-ts=\"1493042509\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GRPN\" target=\"_blank\">GRPN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3258956-grouponminus-3-morgan-stanley-cuts-to-underweight\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Groupon -3% as Morgan Stanley cuts to Underweight</a></h4><ul>   <li>Groupon (NASDAQ:<a href='https://seekingalpha.com/symbol/GRPN' title='Groupon, Inc.'>GRPN</a>) is <font color='red'>off 3%</font> after a Morgan Stanley downgrade to Underweight on what it says is lackluster advertising demand.</li>    <li>The firm's cutting estimates for Groupon's EBITDA by 4% for each of 2017 and 2018, and noting other analysts are likely missing the company's need to spend on advertising for growth.</li>    <li>It's lowered its price target to $3.50 from $3.90, implying 9.8% downside from yesterday's close.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3258956\" data-linked=\"Groupon -3% as Morgan Stanley cuts to Underweight\" data-tweet=\"$GRPN - Groupon -3% as Morgan Stanley cuts to Underweight https://seekingalpha.com/news/3258956-grouponminus-3-morgan-stanley-cuts-to-underweight?source=tweet\" data-url=\"https://seekingalpha.com/news/3258956-grouponminus-3-morgan-stanley-cuts-to-underweight\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:01 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>21&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3258945\" data-ts=\"1493040588\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SONC\" target=\"_blank\">SONC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3258945-stephens-sees-28-upside-for-sonic\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Stephens sees 28% upside for Sonic</a></h4><ul> <li>Stephens <a href=\"https://www.streetinsider.com/Analyst+PT+Change/Stephens+Upgrades+Sonic+%28SONC%29+to+Overweight%2C+Sees+SSS+Inflection+And+Attractive+RiskReward/12803705.html\" target=\"_blank\">upgrades</a> Sonic (NASDAQ:<a href='https://seekingalpha.com/symbol/SONC' title='Sonic Corp.'>SONC</a>) to Overweight after having the restaurant stock lined up at Equal Weight. The risk/reward profile on Sonic is seen as attractive due to the expected track of same-store sales growth.</li> <li>The investment firm takes its price target up to $32 to rep 28% upside potential for shares. The 52-week high on Sonic is $35.72.</li>   </ul><div class=\"tiny-share-widget\" data-id=\"3258945\" data-linked=\"Stephens sees 28% upside for Sonic\" data-tweet=\"$SONC - Stephens sees 28% upside for Sonic https://seekingalpha.com/news/3258945-stephens-sees-28-upside-for-sonic?source=tweet\" data-url=\"https://seekingalpha.com/news/3258945-stephens-sees-28-upside-for-sonic\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:29 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3258942\" data-ts=\"1493039863\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DHT\" target=\"_blank\">DHT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3258942-dht-holdings-takes-delivery-of-two-vlccs\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">DHT Holdings takes delivery of two VLCCs</a></h4><ul>        <li>DHT Holdings (NYSE:<a href='https://seekingalpha.com/symbol/DHT' title='DHT Holdings, Inc.'>DHT</a>) announces that it took delivery of the DHT Opal and the DHT Raven.</li><li>The two vessels are the second and third of the VLCCs acquired from BW Group Limited, with the remaining six vessels expected to be delivered later during Q2.</li>     <li>DHT  <font color='green'>+2.83%</font> premarket to  $4.73.</li>     <li>Source: <a href=\"https://seekingalpha.com/pr/16807095-dht-holdings-inc-announces-delivery-two-vlccs-bw-group\" target=\"_blank\">Press Release</a></li> </ul><div class=\"tiny-share-widget\" data-id=\"3258942\" data-linked=\"DHT Holdings takes delivery of two VLCCs\" data-tweet=\"$DHT - DHT Holdings takes delivery of two VLCCs https://seekingalpha.com/news/3258942-dht-holdings-takes-delivery-of-two-vlccs?source=tweet\" data-url=\"https://seekingalpha.com/news/3258942-dht-holdings-takes-delivery-of-two-vlccs\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:17 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3258940\" data-ts=\"1493039712\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/IMNP\" target=\"_blank\">IMNP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3258940-immune-pharma-restructures-ahead-of-possible-spin-off-of-cytovia-unit-shares-down-9-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Immune Pharma restructures ahead of possible spin-off of Cytovia unit; shares down 9% premarket</a></h4><ul><li>Immune Pharmaceuticals (<a href='https://seekingalpha.com/symbol/IMNP' title='Immune Pharmaceuticals Inc.'>OTCQB:IMNP</a>) slips&nbsp;<font color='red'>9%</font>&nbsp;premarket on modest volume in response to its <a href=\"https://seekingalpha.com/pr/16807331-immune-pharmaceuticals-announces-corporate-restructuring\" target=\"_blank\">announcement </a>that it will restructure its operations in order to position itself for a potential spin-out of subsidiary Cytovia.</li><li>Cytovia focuses on developing immuno-oncology and hematology therapeutics, led by leukemia candidate Ceplene (histamine dihydrochloride). Former Immune CEO Dr. Daniel Teper will lead the business.</li><li>Board member Elliot Maza will lead Immune on an interim basis unit a new CEO is appointed.</li></ul><div class=\"tiny-share-widget\" data-id=\"3258940\" data-linked=\"Immune Pharma restructures ahead of possible spin-off of Cytovia unit; shares down 9% premarket\" data-tweet=\"$IMNP $IMNPQ - Immune Pharma restructures ahead of possible spin-off of Cytovia unit; shares down 9% premarket https://seekingalpha.com/news/3258940-immune-pharma-restructures-ahead-of-possible-spin-off-of-cytovia-unit-shares-down-9-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3258940-immune-pharma-restructures-ahead-of-possible-spin-off-of-cytovia-unit-shares-down-9-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:15 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>8&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3258939\" data-ts=\"1493039597\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FRGI\" target=\"_blank\">FRGI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3258939-fiesta-restaurant-group-announces-strategy-reset\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Fiesta Restaurant Group announces strategy reset</a></h4><ul>          <li>Fiesta Restaurant Group (NASDAQ:<a href='https://seekingalpha.com/symbol/FRGI' title='Fiesta Restaurant Group, Inc.'>FRGI</a>)&nbsp;announces some of the steps that it's taking as part of a value creation plan.</li>     <li>The company says it intends to relaunch the Pollo       Tropical brand in September of this year and to relaunch the Taco Cabana       brand late in the year once priority initiatives under the plan       are achieved.</li>     <li>Priority initiatives include the revitalizing brands in core markets, managing capital and financial discipline, establishing new platforms for long term growth and store closings.</li>     <li>The store closing include all Pollo Tropical locations in         Dallas-Fort Worth,&nbsp;Austin&nbsp;and Nashville.</li>     <li>&ldquo;Fiesta&rsquo;s recent growth initiatives diverted       resources from our core markets and some amount of renewal is required       to restore momentum in these markets,\" says CEO Richard Stockinger.</li>     <li>FRGI  <font color='red'>-6.07%</font> premarket to  $22.45.</li>     <li>Source: <a href=\"https://seekingalpha.com/pr/16807348-fiesta-restaurant-group-inc-announces-strategic-renewal-plan-drive-long-term-value-creation\" target=\"_blank\">Press Release</a></li> </ul><div class=\"tiny-share-widget\" data-id=\"3258939\" data-linked=\"Fiesta Restaurant Group announces strategy reset\" data-tweet=\"$FRGI - Fiesta Restaurant Group announces strategy reset https://seekingalpha.com/news/3258939-fiesta-restaurant-group-announces-strategy-reset?source=tweet\" data-url=\"https://seekingalpha.com/news/3258939-fiesta-restaurant-group-announces-strategy-reset\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:13 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3258938\" data-ts=\"1493039545\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3258938-premarket-gainers-of-9-05\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Premarket Gainers as of 9:05 am</a></h4><ul><li><a href='https://seekingalpha.com/symbol/OPTT' title='Ocean Power Technologies, Inc.'>OPTT</a> <font color='green'>+78%</font>&nbsp;on <a href=\"https://seekingalpha.com/pr/16806721-ocean-power-technologies-announces-deployment-pb3-powerbuoy-japan\" target=\"_blank\">announcing</a> the deployment of its PB3 PowerBuoy in Japan.</li><li><a href='https://seekingalpha.com/symbol/RGSE' title='RGS Energy, Inc.'>RGSE</a> <font color='green'>+30%</font>.</li><li><a href='https://seekingalpha.com/symbol/BCR' title='C. R. Bard, Inc.'>BCR</a> <font color='green'>+20%</font>.</li><li><a href='https://seekingalpha.com/symbol/DB' title='Deutsche Bank AG'>DB</a> <font color='green'>+10%</font>.</li><li><a href='https://seekingalpha.com/symbol/SCYX' title='SCYNEXIS, Inc.'>SCYX</a> <font color='green'>+9%</font>&nbsp;on <a href=\"https://seekingalpha.com/pr/16806305-scynexis-host-conference-call-discuss-lead-anti-infective-candidate-scyminus-078-data\" target=\"_blank\">announcing</a> <em>vitro</em>&nbsp;and clinical data related to its lead candidate, SCY-078.</li><li><a href='https://seekingalpha.com/symbol/BBVA' title='Banco Bilbao Vizcaya Argentaria, S.A.'>BBVA</a> <font color='green'>+8%</font>.</li><li><a href='https://seekingalpha.com/symbol/ING' title='ING Groep N.V.'>ING</a> <font color='green'>+7%</font>.</li><li><a href='https://seekingalpha.com/symbol/SAN' title='Banco Santander S.A.'>SAN</a> <font color='green'>+6%</font>.</li><li><a href='https://seekingalpha.com/symbol/HAS' title='Hasbro, Inc.'>HAS</a> <font color='green'>+5%</font>&nbsp;on <a href=\"https://seekingalpha.com/news/3258857-hasbro-beats-0_05-beats-revenue\" target=\"_blank\">announcing</a> Q1 beat.</li><li><a href='https://seekingalpha.com/symbol/UBS' title='UBS Group AG'>UBS</a> <font color='green'>+5%</font>.</li><li><a href='https://seekingalpha.com/symbol/BCS' title='Barclays PLC'>BCS</a> <font color='green'>+5%</font>.</li><li><a href='https://seekingalpha.com/symbol/PHG' title='Koninklijke Philips NV'>PHG</a> <font color='green'>+5%</font>&nbsp;on <a href=\"https://seekingalpha.com/news/3258846-koninklijke-philips-nv-reports-q1-results\" target=\"_blank\">reporting</a> Q1 result.</li></ul><div class=\"tiny-share-widget\" data-id=\"3258938\" data-linked=\"Premarket Gainers as of 9:05 am\" data-tweet=\"$OPTT $RGSE $BCR - Premarket Gainers as of 9:05 am https://seekingalpha.com/news/3258938-premarket-gainers-of-9-05?source=tweet\" data-url=\"https://seekingalpha.com/news/3258938-premarket-gainers-of-9-05\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:12 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3258936\" data-ts=\"1493039319\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3258936-premarket-losers-of-9-05\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Premarket Losers as of 9:05 am</a></h4><ul>     <li><a href='https://seekingalpha.com/symbol/IMNP' title='Immune Pharmaceuticals Inc.'>OTCQB:IMNP</a> <font color='red'>-9%</font>&nbsp;on <a href=\"https://seekingalpha.com/pr/16807331-immune-pharmaceuticals-announces-corporate-restructuring\" target=\"_blank\">announcing</a> corporate restructuring.</li><li><a href='https://seekingalpha.com/symbol/GFI' title='Gold Fields Limited'>GFI</a> <font color='red'>-7%</font>.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3258936\" data-linked=\"Premarket Losers as of 9:05 am\" data-tweet=\"$IMNPQ $GFI - Premarket Losers as of 9:05 am https://seekingalpha.com/news/3258936-premarket-losers-of-9-05?source=tweet\" data-url=\"https://seekingalpha.com/news/3258936-premarket-losers-of-9-05\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:08 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3258926\" data-ts=\"1493038612\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/KWERF\" target=\"_blank\">KWERF</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3258926-kennedy-wilson-to-merge-kw-europe\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Kennedy-Wilson to merge with KW Europe</a></h4><ul><li>Under the terms of the deal, Kennedy Willson Europe (<a href='https://seekingalpha.com/symbol/KWERF' title='Kennedy Wilson Europe Real Estate PLC'>OTC:KWERF</a>) owners will receive 0.667 new Kennedy-Wilson (NYSE:<a href='https://seekingalpha.com/symbol/KW' title='Kennedy-Wilson Holdings, Inc.'>KW</a>) shares each share of KWE they hold. Based on current prices, that's a&nbsp;<font color='green'>20% premium</font>&nbsp;to KWE's close on Friday.</li><li>Kennedy-Wilson intends to boost its dividend by 12% upon closing the transaction.</li><li>The combined company will have a market cap of about $4B and an enterprise value of roughly $8.2B, and the hope is the greater scale will be a boon for operations, and in representation in market indices.</li><li>A <a href=\"http://event.on24.com/wcc/r/1414749-1/EFCEFA744FBC9C1C6596BC9FB879D24B\" target=\"_blank\">conference call</a> is underway.</li><li><a href='https://seekingalpha.com/symbol/KW' title='Kennedy-Wilson Holdings, Inc.'>KW</a><font color='red'> -2.2%</font>&nbsp;premarket</li></ul><div class=\"tiny-share-widget\" data-id=\"3258926\" data-linked=\"Kennedy-Wilson to merge with KW Europe\" data-tweet=\"$KWERF $KWERF $KW - Kennedy-Wilson to merge with KW Europe https://seekingalpha.com/news/3258926-kennedy-wilson-to-merge-kw-europe?source=tweet\" data-url=\"https://seekingalpha.com/news/3258926-kennedy-wilson-to-merge-kw-europe\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:56 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3258920\" data-ts=\"1493037357\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SCYX\" target=\"_blank\">SCYX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3258920-scynexis-up-11-premarket-ahead-of-scyminus-078-data\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">SCYNEXIS up 11% premarket ahead of SCY-078 data</a></h4><ul><li>Thinly traded nano cap SCYNEXIS (NASDAQ:<a href='https://seekingalpha.com/symbol/SCYX' title='SCYNEXIS, Inc.'>SCYX</a>) is up&nbsp;<font color='green'>11%</font>&nbsp;premarket on light volume as traders take positions ahead of the <a href=\"https://seekingalpha.com/pr/16806305-scynexis-host-conference-call-discuss-lead-anti-infective-candidate-scyminus-078-data\" target=\"_blank\">conference call </a>scheduled for tomorrow at 4:05 ET to discuss data related to lead product candidate SCY-078 that are being presented at the European Congress of Clinical Microbiology and Infectious Diseases ((ECCMID)) in Vienna.</li><li>SCY-078, an inhibitor of an enzyme called&nbsp;<a href=\"https://en.wikipedia.org/wiki/1,3-Beta-glucan_synthase\" target=\"_blank\">glucan synthase</a>, is active against multi-drug-resistant pathogens, including those resistant to echinocandins, a class of antifungal drugs.&nbsp;</li><li>Previously: <a href=\"https://seekingalpha.com/news/3250394-scynexis-spikes-8-percent-reports-deadly-fungal-infection-u-s-treated-lead-product-candidate\" target=\"_blank\">SCYNEXIS spikes 8% on reports of deadly fungal infection in U.S. that could be treated with lead product candidate SCY-078</a> (March 10)</li></ul><div class=\"tiny-share-widget\" data-id=\"3258920\" data-linked=\"SCYNEXIS up 11% premarket ahead of SCY-078 data\" data-tweet=\"$SCYX - SCYNEXIS up 11% premarket ahead of SCY-078 data https://seekingalpha.com/news/3258920-scynexis-up-11-premarket-ahead-of-scyminus-078-data?source=tweet\" data-url=\"https://seekingalpha.com/news/3258920-scynexis-up-11-premarket-ahead-of-scyminus-078-data\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:35 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3258915\" data-ts=\"1493036481\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BAC\" target=\"_blank\">BAC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3258915-u-s-banks-set-for-big-day-amid-european-rally-bofa-downgraded\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">U.S. banks set for big day amid European rally; BofA downgraded</a></h4><ul><li>A major rally is underway in Europe following Sunday's French election. Leading the way <a href=\"https://seekingalpha.com/news/3258883-european-banks-lead-post-election-rally-deutsche-10-percent\" target=\"_blank\">are the banks</a>, as the election result seems to assure status quo in the EU. Deutsche Bank is<font color='green'> higher by 10.3%</font>.</li><li>U.S. banks are also outperforming about a rise in S&amp;P 500 futures. Bank of America (NYSE:<a href='https://seekingalpha.com/symbol/BAC' title='Bank of America Corporation'>BAC</a>), Goldman Sachs (NYSE:<a href='https://seekingalpha.com/symbol/GS' title='Goldman Sachs Group Inc.'>GS</a>), Citigroup (NYSE:<a href='https://seekingalpha.com/symbol/C' title='Citigroup Inc.'>C</a>), JPMorgan (NYSE:<a href='https://seekingalpha.com/symbol/JPM' title='JPMorgan Chase & Co.'>JPM</a>), and Morgan Stanley (NYSE:<a href='https://seekingalpha.com/symbol/MS' title='Morgan Stanley'>MS</a>) are all&nbsp;<font color='green'>up 2% or more</font>&nbsp;in premarket action.</li><li><a href='https://seekingalpha.com/symbol/KBE' title='SPDR S&P Bank ETF'>KBE</a>&nbsp;<font color='green'>+2.6%</font>, <a href='https://seekingalpha.com/symbol/KRE' title='SPDR S&P Regional Banking ETF'>KRE</a>&nbsp;<font color='green'>+2.7%</font>, <a href='https://seekingalpha.com/symbol/XLF' title='Financial Select Sector SPDR ETF'>XLF</a>&nbsp;<font color='green'>+2.25%</font></li><li>Berenberg's James Chappell overnight said it was time to take profits in Bank of America after its 50% Y/Y run. Higher interest rates, lower tax rates, and eased deregulation have all been priced in, he says, and there could be disappointment coming in each of those three areas. He downgrades to Hold from Buy.</li><li>As for interest rates, the low-rate scare of 2017 could be at an end. After falling as low as 2.16% at one point last week, the 10-year Treasury yield is up another seven basis points this morning to 2.31%.</li></ul><div class=\"tiny-share-widget\" data-id=\"3258915\" data-linked=\"U.S. banks set for big day amid European rally; BofA downgraded\" data-tweet=\"$BAC $BAC $GS - U.S. banks set for big day amid European rally; BofA downgraded https://seekingalpha.com/news/3258915-u-s-banks-set-for-big-day-amid-european-rally-bofa-downgraded?source=tweet\" data-url=\"https://seekingalpha.com/news/3258915-u-s-banks-set-for-big-day-amid-european-rally-bofa-downgraded\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:21 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>18&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3258913\" data-ts=\"1493036183\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/LII\" target=\"_blank\">LII</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3258913-on-lennoxs-q1\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">More on Lennox&#39;s Q1</a></h4><ul>     <li>Lennox (NYSE:<a href='https://seekingalpha.com/symbol/LII' title='Lennox International Inc.'>LII</a>) reports&nbsp;Residential Heating &amp; Cooling segment revenue rose 11% to $420M in <a href=\"https://seekingalpha.com/pr/16807206-lennox-international-reports-record-first-quarter-revenue-profit\" target=\"_blank\">Q1</a>.</li>     <li>Commercial Heating &amp; Cooling segment revenue grew 15% to $196M.</li>     <li>Refrigeration segment revenue expanded 6% to $178M.</li>     <li>Gross margin rate advanced 90 bps to 26.6% higher volume and lower material costs.</li>     <li>Residential Heating &amp; Cooling operating margin rate -10 bps to 10.1%.</li>     <li>Commercial Heating and Cooling operating margin rate up 150 bps to 9.8%.</li>     <li>Refrigeration operating margin rate improved 250 bps to 7.9%<b>.</b></li>     <li><b>FY2017 Guidance</b>: Revenue: +3% to +7%; Adjusted and GAAP EPS: $7.55 to $8.15; Tax rate: ~32%; Share count: ~42M to 43M; Capex: ~$100M; Stock repurchase: $250M.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3258913\" data-linked=\"More on Lennox&#39;s Q1\" data-tweet=\"$LII - More on Lennox&#39;s Q1 https://seekingalpha.com/news/3258913-on-lennoxs-q1?source=tweet\" data-url=\"https://seekingalpha.com/news/3258913-on-lennoxs-q1\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:16 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3258896\" data-ts=\"1493035929\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PDLI\" target=\"_blank\">PDLI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3258896-pdl-biopharma-settles-keytruda-patent-infringement-lawsuit-merck\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">PDL Biopharma settles keytruda patent infringement lawsuit with Merck</a></h4><ul> <li>PDL BioPharma (NASDAQ:<a href='https://seekingalpha.com/symbol/PDLI' title='PDL BioPharma, Inc.'>PDLI</a>) <a href=\"https://seekingalpha.com/pr/16807057-pdl-biopharma-announces-settlement-keytruda-patent-infringement-lawsuit-merck\" target=\"_blank\">announces</a> that it has entered into a settlement agreement with certain subsidiaries of Merck (NYSE:<a href='https://seekingalpha.com/symbol/MRK' title='Merck & Co Inc.'>MRK</a>) to resolve their patent infringement lawsuit related to Keytruda (pembrolizumab).</li><li>Under the terms of the agreement, Merck will pay PDLI $19.5M in exchange for a fully paid-up, royalty free, non-exclusive license to certain patent rights related to Keytruda while PDLI has agreed not to sue Merck for royalties. Both parties have agreed to dismiss all claims related to the litigation.</li><li>PDLI is up&nbsp;<font color='green'>4%</font>&nbsp;premarket on light volume.</li></ul><div class=\"tiny-share-widget\" data-id=\"3258896\" data-linked=\"PDL Biopharma settles keytruda patent infringement lawsuit with Merck\" data-tweet=\"$PDLI $PDLI $MRK - PDL Biopharma settles keytruda patent infringement lawsuit with Merck https://seekingalpha.com/news/3258896-pdl-biopharma-settles-keytruda-patent-infringement-lawsuit-merck?source=tweet\" data-url=\"https://seekingalpha.com/news/3258896-pdl-biopharma-settles-keytruda-patent-infringement-lawsuit-merck\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:12 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3258910\" data-ts=\"1493035929\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AKS\" target=\"_blank\">AKS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3258910-macquarie-upgrades-steelmakers-u-s-steelplus-2_5\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Macquarie upgrades the steelmakers; U.S. Steel +2.5%</a></h4><ul><li>via Bloomberg</li><li>Upped to Outperform from Neutral are AK Steel (NYSE:<a href='https://seekingalpha.com/symbol/AKS' title='AK Steel Holding Corp'>AKS</a>) and Steel Dynamics (NASDAQ:<a href='https://seekingalpha.com/symbol/STLD' title='Steel Dynamics, Inc.'>STLD</a>). Lifted to Neutral from Underperform are U.S. Steel (NYSE:<a href='https://seekingalpha.com/symbol/X' title='United States Steel Corporation'>X</a>) and Nucor (NYSE:<a href='https://seekingalpha.com/symbol/NUE' title='Nucor Corporation'>NUE</a>).</li><li>On a high level, analyst Aldo&nbsp;Mazzaferro says earnings so far (STLD and NUE have reported) show evidence of improving demand, which should result in better volumes and pricing.</li><li>For U.S. Steel,&nbsp;Mazzaferro takes note of indicators showing improvement in energy and industrial markets, two area where X has good exposure.</li><li>X&nbsp;<font color='green'>+2.5%</font>, NUE&nbsp;<font color='green'>+1.1%</font>,&nbsp;<font color='green'>+2.8%</font>&nbsp;premarket</li></ul><div class=\"tiny-share-widget\" data-id=\"3258910\" data-linked=\"Macquarie upgrades the steelmakers; U.S. Steel +2.5%\" data-tweet=\"$AKS $AKS $STLD - Macquarie upgrades the steelmakers; U.S. Steel +2.5% https://seekingalpha.com/news/3258910-macquarie-upgrades-steelmakers-u-s-steelplus-2_5?source=tweet\" data-url=\"https://seekingalpha.com/news/3258910-macquarie-upgrades-steelmakers-u-s-steelplus-2_5\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:12 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>13&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3258890\" data-ts=\"1493034484\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/KMB\" target=\"_blank\">KMB</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3258890-on-kimberly-clarks-q1\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">More on Kimberly-Clark&#39;s Q1</a></h4><ul>     <li>Kimberly-Clark (NYSE:<a href='https://seekingalpha.com/symbol/KMB' title='Kimberly-Clark Corporation'>KMB</a>) reports organic sales fell 1% in <a href=\"https://seekingalpha.com/pr/16807125-kimberly-clark-announces-first-quarter-2017-results\" target=\"_blank\">Q1</a>.</li>     <li>North American consumer products organic sales dropped 3%, reflecting category softness, competitive activity and less promotion shipments.</li>     <li>Developing and emerging markets saw organic growth of 4% for the period.</li>     <li>Foreign currency exchange rates increased sales by 1%.</li>     <li>Segment revenue: Personal care: $2.25B (+2%); Consumer Tissue: $1.46B (-3%); K-C Professional: $768M (+1%).</li>     <li>Adjusted gross margin rate improved 30 bps to 36.9%.</li>     <li>Segment operating profit:&nbsp;Personal care: $481M (+7%); Consumer Tissue: $275M (-2%); K-C Professional: $146M (-3%).</li>     <li>Adjusted operating margin rate +30 bps to 18.6%.</li>     <li><b>FY2017 Guidance</b>: Net sales: +1% to +2%; Organic sales: +1% to +2%; Tax rate:&nbsp;30.7%;&nbsp;Adjusted EPS: $6.2 to $6.35.</li>     <li>KMB&nbsp;<font color='red'>-0.43%</font>&nbsp;premarket.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3258890\" data-linked=\"More on Kimberly-Clark&#39;s Q1\" data-tweet=\"$KMB - More on Kimberly-Clark&#39;s Q1 https://seekingalpha.com/news/3258890-on-kimberly-clarks-q1?source=tweet\" data-url=\"https://seekingalpha.com/news/3258890-on-kimberly-clarks-q1\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:48 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3258883\" data-ts=\"1493033423\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DB\" target=\"_blank\">DB</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3258883-european-banks-lead-post-election-rally-deutsche-up-10\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">European banks lead post-election rally; Deutsche up 10%</a></h4><ul><li>Breathing the largest size of relief <a href=\"https://seekingalpha.com/news/3258875-europe-skies-french-election\" target=\"_blank\">after the French presidential election</a> are the banks, which seemingly are leveraged more than most to the status quo of the EU, the euro, and the ECB's QE.</li><li>Deutsche Bank ADRs (NYSE:<a href='https://seekingalpha.com/symbol/DB' title='Deutsche Bank AG'>DB</a>) are&nbsp;<font color='green'>up 10%</font>&nbsp;in premarket action; Santander (NYSE:<a href='https://seekingalpha.com/symbol/SAN' title='Banco Santander S.A.'>SAN</a>)&nbsp;<font color='green'>+6.4%</font>, <a href='https://seekingalpha.com/symbol/BBVA' title='Banco Bilbao Vizcaya Argentaria, S.A.'>BBVA</a>&nbsp;<font color='green'>+7.35%</font>, Credit Suisse (NYSE:<a href='https://seekingalpha.com/symbol/CS' title='Credit Suisse Group AG'>CS</a>)&nbsp;<font color='green'>+5%</font>, <a href='https://seekingalpha.com/symbol/UBS' title='UBS Group AG'>UBS</a>&nbsp;<font color='green'>+6.5%</font>, <a href='https://seekingalpha.com/symbol/ING' title='ING Groep N.V.'>ING</a>&nbsp;<font color='green'>+7.5%</font>.</li><li>U.K. lenders: <a href='https://seekingalpha.com/symbol/RBS' title='The Royal Bank of Scotland Group plc'>RBS</a>&nbsp;<font color='green'>+1.95%</font>, Barclays (NYSE:<a href='https://seekingalpha.com/symbol/BCS' title='Barclays PLC'>BCS</a>)&nbsp;<font color='green'>+5.8%</font>, <a href='https://seekingalpha.com/symbol/HSBC' title='HSBC Holdings PLC'>HSBC</a>&nbsp;<font color='green'>+2.35%</font>, Lloyds (NYSE:<a href='https://seekingalpha.com/symbol/LYG' title='Lloyds Banking Group plc'>LYG</a>)&nbsp;<font color='green'>+3.6%</font>.</li><li>ETF: <a href='https://seekingalpha.com/symbol/EUFN' title='iShares MSCI Europe Financials Sector Index ETF'>EUFN</a>&nbsp;<font color='green'>+5.7%</font></li><li>The broader Stoxx 600 is&nbsp;<font color='green'>up 2%</font>, led by France's&nbsp;<font color='green'>4.5% gain</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3258883\" data-linked=\"European banks lead post-election rally; Deutsche up 10%\" data-tweet=\"$DB $DB $SAN - European banks lead post-election rally; Deutsche up 10% https://seekingalpha.com/news/3258883-european-banks-lead-post-election-rally-deutsche-up-10?source=tweet\" data-url=\"https://seekingalpha.com/news/3258883-european-banks-lead-post-election-rally-deutsche-up-10\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:30 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>12&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3258876\" data-ts=\"1493032861\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/LLY\" target=\"_blank\">LLY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3258876-lillys-abemaciclib-successful-in-late-stage-breast-cancer-study-shares-ahead-1-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Lilly&#39;s abemaciclib successful in late-stage breast cancer study; shares ahead 1% premarket</a></h4><ul><li>Eli Lilly (NYSE:<a href='https://seekingalpha.com/symbol/LLY' title='Eli Lilly and Company'>LLY</a>) is up&nbsp;<font color='green'>1%</font>&nbsp;premarket, albeit on only 77 shares, after its announcement of <a href=\"https://seekingalpha.com/pr/16807023-lilly-announces-phase-3-monarch-3-breast-cancer-study-abemaciclib-demonstrated-superior\" target=\"_blank\">positive results</a> from a Phase 3 clinical trial, <a href=\"https://clinicaltrials.gov/ct2/show/NCT02246621?term=abemaciclib&amp;phase=2&amp;rank=4\" target=\"_blank\">MONARCH 3</a>, evaluating abemaciclib in adult patients with HR+, HER2- advanced breast cancer.</li><li>The study met its primary endpoint of progression-free survival &#40;PFS&#41; and showed improvement in objective response rate &#40;ORR&#41;, a secondary endpoint. Detailed results will be presented at a medical conference in H2.</li><li>The company says it will commence global submissions of the results in Q3. The submission of results from two other Phase 3s, MONARCH 1 and MONARCH 2, will be initiated this quarter.</li><li>Breakthrough Therapy-tagged abemaciclib is a cell cycle inhibitor that is designed to block the growth of cancer cells by inhibiting the enzymes&nbsp;<a href=\"https://en.wikipedia.org/wiki/Cyclin-dependent_kinase_4\" target=\"_blank\">CDK4&nbsp;</a>and&nbsp;<a href=\"https://en.wikipedia.org/wiki/Cyclin-dependent_kinase_6\" target=\"_blank\">CDK6</a>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3258876\" data-linked=\"Lilly&#39;s abemaciclib successful in late-stage breast cancer study; shares ahead 1% premarket\" data-tweet=\"$LLY - Lilly&#39;s abemaciclib successful in late-stage breast cancer study; shares ahead 1% premarket https://seekingalpha.com/news/3258876-lillys-abemaciclib-successful-in-late-stage-breast-cancer-study-shares-ahead-1-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3258876-lillys-abemaciclib-successful-in-late-stage-breast-cancer-study-shares-ahead-1-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:21 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3258875\" data-ts=\"1493032462\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3258875-europe-skies-after-french-election\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Europe skies after French election</a></h4><ul><li>Marine Le Pen made it to the runoff round in the French presidential election, but <a href=\"http://www.marketwatch.com/story/us-stocks-poised-to-rally-as-investors-breathe-sigh-of-relief-over-french-vote-2017-04-24\" target=\"_blank\">pollsters assure she </a>has no shot at winning the two-person race (set for May 7).</li><li>Europe's Stoxx 600 is celebrating,&nbsp;<font color='green'>up 2.05%</font>, with France's CAC-40 (NYSEARCA:<a href='https://seekingalpha.com/symbol/EWQ' title='iShares MSCI France ETF'>EWQ</a>) leading the charge with a<font color='green'> 4.5% melt-up</font>. Italy (NYSEARCA:<a href='https://seekingalpha.com/symbol/EWI' title='iShares MSCI Italy Capped ETF'>EWI</a>) is&nbsp;<font color='green'>4% higher</font>; Spain (NYSEARCA:<a href='https://seekingalpha.com/symbol/EWP' title='iShares MSCI Spain Capped ETF'>EWP</a>) 3.3%, Germany (NYSEARCA:<a href='https://seekingalpha.com/symbol/EWG' title='iShares MSCI Germany ETF'>EWG</a>)&nbsp;<font color='green'>3%</font>, and the U.K. (NYSEARCA:<a href='https://seekingalpha.com/symbol/EWU' title='iShares MSCI United Kingdom ETF'>EWU</a>)&nbsp;<font color='green'>1.8%</font>.</li><li>The euro is&nbsp;<font color='green'>higher by 1.25%</font>&nbsp;vs. the greenback.</li><li>As for bonds, investors are selling the core, and buying the periphery. The German 10-year Bund yield is up 8.6 basis points to 0.341%, while Italian and Spanish 10-year yields are each down about 9 basis points.</li><li>ETFs: <a href='https://seekingalpha.com/symbol/VGK' title='Vanguard FTSE Europe ETF'>VGK</a>, <a href='https://seekingalpha.com/symbol/HEDJ' title='WisdomTree Europe Hedged Equity ETF'>HEDJ</a>, <a href='https://seekingalpha.com/symbol/FEZ' title='SPDR EURO STOXX 50 ETF'>FEZ</a>, <a href='https://seekingalpha.com/symbol/IEV' title='iShares Europe ETF'>IEV</a>, <a href='https://seekingalpha.com/symbol/EPV' title='ProShares UltraShort FTSE Europe ETF'>EPV</a>, <a href='https://seekingalpha.com/symbol/EZU' title='iShares MSCI Eurozone ETF'>EZU</a>, <a href='https://seekingalpha.com/symbol/FEU' title='SPDR STOXX Europe 50 ETF'>FEU</a>, <a href='https://seekingalpha.com/symbol/EURL' title='Direxion Daily FTSE Europe Bull 3x Shares ETF'>EURL</a>, <a href='https://seekingalpha.com/symbol/DBEU' title='Deutsche X-trackers MSCI Europe Hedged Equity ETF'>DBEU</a>, <a href='https://seekingalpha.com/symbol/EEA' title='European Equity Fund'>EEA</a>, <a href='https://seekingalpha.com/symbol/FEP' title='First Trust Europe AlphaDEX ETF'>FEP</a>, <a href='https://seekingalpha.com/symbol/HEZU' title='iShares Currency Hedged MSCI EMU ETF'>HEZU</a>, <a href='https://seekingalpha.com/symbol/UPV' title='ProShares Ultra FTSE Europe ETF'>UPV</a>, <a href='https://seekingalpha.com/symbol/IEUR' title='iShares Core MSCI Europe ETF'>IEUR</a>, <a href='https://seekingalpha.com/symbol/FEEU' title='Barclays ETN+ FI Enhanced Europe 50 ETN'>FEEU</a>, <a href='https://seekingalpha.com/symbol/ADRU' title='BLDRS Europe 100 ADR Index ETF'>ADRU</a>, <a href='https://seekingalpha.com/symbol/FIEU' title='Credit Suisse FI Enhanced Europe 50 ETN'>FIEU</a>, <a href='https://seekingalpha.com/symbol/DBEZ' title='Deutsche X-trackers MSCI EMU Hedged Equity ETF'>DBEZ</a>, <a href='https://seekingalpha.com/symbol/FEUZ' title='First Trust Eurozone AlphaDex ETF'>FEUZ</a>, <a href='https://seekingalpha.com/symbol/HFEZ' title='SPDR Euro Stoxx 50 Currency Hedged ETF'>HFEZ</a>, <a href='https://seekingalpha.com/symbol/HFXE' title='IQ 50 Percent Hedged FTSE Europe ETF'>HFXE</a>, <a href='https://seekingalpha.com/symbol/DEZU' title='iShares Adaptive Currency Hedged MSCI Eurozone ETF'>DEZU</a>, <a href='https://seekingalpha.com/symbol/FIEE' title='UBS AG FI Enhanced Europe 50 ETN'>FIEE</a>, <a href='https://seekingalpha.com/symbol/GSEU' title='Goldman Sachs ActiveBeta Europe Equity ETF'>GSEU</a>, <a href='https://seekingalpha.com/symbol/HGEU' title='ProShares Hedged FTSE Europe ETF'>HGEU</a>, <a href='https://seekingalpha.com/symbol/PTEU' title='Pacer Trendpilo European Index ETF'>PTEU</a>, <a href='https://seekingalpha.com/symbol/RFEU' title='First Trust RiverFront Dynamic Europe ETF'>RFEU</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3258875\" data-linked=\"Europe skies after French election\" data-tweet=\"$EWQ $EWI $EWP - Europe skies after French election https://seekingalpha.com/news/3258875-europe-skies-after-french-election?source=tweet\" data-url=\"https://seekingalpha.com/news/3258875-europe-skies-after-french-election\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:14 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>9&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3258874\" data-ts=\"1493032154\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ALK\" target=\"_blank\">ALK</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3258874-cowen-sees-lift-for-alaska-air\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Cowen sees more lift for Alaska Air</a></h4><ul> <li>Cowen <a href=\"https://twitter.com/usratings/status/856453706119868416\" target=\"_blank\">upgrades</a> Alaska Air Group (NYSE:<a href='https://seekingalpha.com/symbol/ALK' title='Alaska Air Group, Inc.'>ALK</a>) to an Outperform rating after having the airline stock set at Market Perform.</li> <li>Analyst Helene Becker sees more upside potential from the integration of Virgin America.</li> <li>The investment firm lifts its price target to $103 to rep 16% upside potential. The new PT is 13.55X Cowen's 2017 EPS estimate.</li> <li>ALK <font color='green'>+0.94%</font> premarket to $89.95 vs. a 52-week trading range of $54.51 to $101.42.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3258874\" data-linked=\"Cowen sees more lift for Alaska Air\" data-tweet=\"$ALK - Cowen sees more lift for Alaska Air https://seekingalpha.com/news/3258874-cowen-sees-lift-for-alaska-air?source=tweet\" data-url=\"https://seekingalpha.com/news/3258874-cowen-sees-lift-for-alaska-air\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:09 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3258872\" data-ts=\"1493031838\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/HAS\" target=\"_blank\">HAS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3258872-hasbro-positive-post-q1-results\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Hasbro positive post Q1 results</a></h4><ul>     <li>Hasbro (<a href='https://seekingalpha.com/symbol/HAS' title='Hasbro, Inc.'>HAS</a>) reports revenue rose 2.2% in <a href=\"https://seekingalpha.com/pr/16807015-hasbro-reports-revenue-net-earnings-growth-first-quarter-2017\" target=\"_blank\">Q1</a>&nbsp;due to growth in Franchise Brands,&nbsp;Hasbro Gaming&nbsp;and Emerging Brands.</li>     <li>U.S. and&nbsp;Canada revenue up 2% to 451.6M.</li>     <li>International revenue flat at $345.3M, led by 16% growth in Latin America.</li>     <li>Entertainment and Licensing revenue expanded 24% to $52.7M.</li>     <li>Franchise brand revenue grew 2% to $423.6M and Partner brand revenue down 18% to $213M.</li>     <li>Hasbro gaming revenue increased 43% to $142.9M and Emerging brands rose 25% to $70.2M for the quarter.</li>     <li>Operating margin rate fell 110 bps to 9.2%.</li>     <li>HAS&nbsp;<font color='green'>+2.57%</font>&nbsp;premarket.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3258872\" data-linked=\"Hasbro positive post Q1 results\" data-tweet=\"$HAS - Hasbro positive post Q1 results https://seekingalpha.com/news/3258872-hasbro-positive-post-q1-results?source=tweet\" data-url=\"https://seekingalpha.com/news/3258872-hasbro-positive-post-q1-results\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:03 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3258871\" data-ts=\"1493031789\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SNY\" target=\"_blank\">SNY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3258871-european-ad-comm-backs-sanofi-and-regenerons-sarilumab-for-ra\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">European Ad Comm backs Sanofi and Regeneron&#39;s sarilumab for RA</a></h4><ul><li>The European Medicines Agency's Committee for Medicinal Products for Human Use &#40;CHMP&#41; <a href=\"https://seekingalpha.com/pr/16806903-sanofi-regeneron-receive-chmp-positive-opinion-kevzara-sarilumab-treat-adult-patients\" target=\"_blank\">adopts a positive opinion</a> recommending approval of Sanofi (NASDAQ:<a href='https://seekingalpha.com/symbol/SNY' title='Sanofi'>SNY</a>) and Regeneron Pharmaceuticals' (NASDAQ:<a href='https://seekingalpha.com/symbol/REGN' title='Regeneron Pharmaceuticals, Inc.'>REGN</a>) sarilumab, branded as Kevzara, for the treatment of adult patients with moderately to severely active rheumatoid arthritis &#40;RA&#41;.</li><li>The specific recommended use for sarilumab is in combination with methotrexate &#40;MTX&#41;&nbsp;in adult RA patients who have failed to respond adequately to or are intolerant of one or more disease modifying anti-rheumatic drugs (DMARDs). Sarilumab can be administered as monotherapy in patients who are intolerant of MTX or when treatment with MTX is inappropriate.</li><li>A final decision from the European Commission usually takes ~60 days.</li><li>Kevzara is currently approved for sale in Canada. The marketing application in the U.S. is currently under FDA review.</li><li>SNY is up&nbsp;<font color='green'>5%</font>&nbsp;premarket but only on 250 shares. No premarket action for REGN has been reported yet.</li></ul><div class=\"tiny-share-widget\" data-id=\"3258871\" data-linked=\"European Ad Comm backs Sanofi and Regeneron&#39;s sarilumab for RA\" data-tweet=\"$SNY $SNY $REGN - European Ad Comm backs Sanofi and Regeneron&#39;s sarilumab for RA https://seekingalpha.com/news/3258871-european-ad-comm-backs-sanofi-and-regenerons-sarilumab-for-ra?source=tweet\" data-url=\"https://seekingalpha.com/news/3258871-european-ad-comm-backs-sanofi-and-regenerons-sarilumab-for-ra\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:03 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3258869\" data-ts=\"1493031726\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TRUE\" target=\"_blank\">TRUE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3258869-truecar-announces-public-offering\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">TrueCar announces public offering</a></h4><ul> <li>TrueCar (NASDAQ:<a href='https://seekingalpha.com/symbol/TRUE' title='TrueCar, Inc'>TRUE</a>) announces a public offering of shares of 8.5M shares.</li><li>TrueCar expects to offer 1M shares of common stock in the offering and certain existing stockholders of the company are expected to offer 7.5M shares. The automotive pricing service firm will not receive any proceeds from the sale of the shares by the selling stockholders.</li><li>TRUE  <font color='red'>-1.31%</font> premarket to  $15.06.</li><li>Source: <a href=\"https://seekingalpha.com/pr/16807008-truecar-announces-proposed-public-offering\" target=\"_blank\">Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3258869\" data-linked=\"TrueCar announces public offering\" data-tweet=\"$TRUE - TrueCar announces public offering https://seekingalpha.com/news/3258869-truecar-announces-public-offering?source=tweet\" data-url=\"https://seekingalpha.com/news/3258869-truecar-announces-public-offering\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:02 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3258855\" data-ts=\"1493029639\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/EDU\" target=\"_blank\">EDU</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3258855-on-new-oriental-education-technologys-q3\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">More on New Oriental Education &amp; Technology&#39;s Q3</a></h4><ul>     <li>New Oriental Education &amp; Technology (NYSE:<a href='https://seekingalpha.com/symbol/EDU' title='New Oriental Education & Technology Group Inc.'>EDU</a>) reports&nbsp;Educational programs and services revenue rose 26% to $397.8M in <a href=\"https://seekingalpha.com/pr/16806949-new-oriental-announces-results-third-fiscal-quarter-ended-february-28-2017\" target=\"_blank\">Q3</a>, driven by increases in student enrollments in academic subjects tutoring and test preparation courses in the recent two quarters.</li>     <li>Books and others revenue increased 27.9% to $43.05M.</li>     <li>K-12 after-school tutoring business revenue up 41%.</li>     <li>Total student enrollments grew 5.9% Y/Y to ~799,700.</li>     <li>The total number of schools and learning centers +77 Y/Y to 803.</li>     <li>Operating margin rate grew 90 bps to 13.1%.</li>     <li><b>Q4 Guidance</b>: Total net revenues: $465.1M to $479.9M (+18% to +22% Y/Y).</li>     <li>EDU&nbsp;<font color='green'>+4%</font>&nbsp;premarket.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3258855\" data-linked=\"More on New Oriental Education &amp; Technology&#39;s Q3\" data-tweet=\"$EDU - More on New Oriental Education &amp; Technology&#39;s Q3 https://seekingalpha.com/news/3258855-on-new-oriental-education-technologys-q3?source=tweet\" data-url=\"https://seekingalpha.com/news/3258855-on-new-oriental-education-technologys-q3\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  6:27 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3258846\" data-ts=\"1493027199\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PHG\" target=\"_blank\">PHG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3258846-koninklijke-philips-nv-reports-q1-results\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Koninklijke Philips NV reports Q1 results</a></h4><ul><li>Koninklijke Philips NV (NYSE:<a href='https://seekingalpha.com/symbol/PHG' title='Koninklijke Philips NV'>PHG</a>): Q1 EPS of&nbsp;&euro;0.25</li><li>Revenue of&nbsp;&euro;5.72B (+3.6% Y/Y)</li><li>Shares <font color='green'>+1.29%</font> PM.</li><li><a href=\"http://www.philips.com/static/qr/2017/q1/philips-first-quarter-results-2017-report.pdf\" target=\"_blank\">Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3258846\" data-linked=\"Koninklijke Philips NV reports Q1 results\" data-tweet=\"$PHG - Koninklijke Philips NV reports Q1 results https://seekingalpha.com/news/3258846-koninklijke-philips-nv-reports-q1-results?source=tweet\" data-url=\"https://seekingalpha.com/news/3258846-koninklijke-philips-nv-reports-q1-results\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:46 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3258842\" data-ts=\"1493026579\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/EDU\" target=\"_blank\">EDU</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3258842-new-oriental-education-and-amp-technology-beats-0_02-beats-on-revenue\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">New Oriental Education &amp;amp; Technology beats by $0.02, beats on revenue</a></h4><ul><li>New Oriental Education &amp; Technology (NYSE:<a href='https://seekingalpha.com/symbol/EDU' title='New Oriental Education & Technology Group Inc.'>EDU</a>): Q3 EPS of $0.43 <font color='green'>beats by $0.02</font>.</li><li>Revenue of $437.85M (+26.2% Y/Y) <font color='green'>beats by $18.14M</font>.</li><li>Shares <font color='green'>+4%</font> PM.</li><li><a href='https://seekingalpha.com/pr/16806949-new-oriental-announces-results-third-fiscal-quarter-ended-february-28-2017'>Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3258842\" data-linked=\"New Oriental Education &amp;amp; Technology beats by $0.02, beats on revenue\" data-tweet=\"$EDU - New Oriental Education &amp; Technology beats by $0.02, beats on revenue https://seekingalpha.com/news/3258842-new-oriental-education-and-amp-technology-beats-0_02-beats-on-revenue?source=tweet\" data-url=\"https://seekingalpha.com/news/3258842-new-oriental-education-and-amp-technology-beats-0_02-beats-on-revenue\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:36 AM </div></div></li>","count":64,"message":null,"success":true,"today":{"start":1577077200,"end":1577163599,"str":"Monday, December 23, 2019"},"yesterday":{"start":1576990800,"end":1577077199}}